BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Takaki A, Wiese M, Maertens G, Depla E, Seifert U, Liebetrau A, Miller JL, Manns MP, Rehermann B. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med. 2000;6:578-582. [PMID: 10802716 DOI: 10.1038/75063] [Cited by in Crossref: 541] [Cited by in F6Publishing: 526] [Article Influence: 24.6] [Reference Citation Analysis]
Number Citing Articles
1 Chigbu DI, Loonawat R, Sehgal M, Patel D, Jain P. Hepatitis C Virus Infection: Host⁻Virus Interaction and Mechanisms of Viral Persistence. Cells 2019;8:E376. [PMID: 31027278 DOI: 10.3390/cells8040376] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 12.0] [Reference Citation Analysis]
2 Pawlotsky J. Use and interpretation of hepatitis C virus diagnostic assays. Clinics in Liver Disease 2003;7:127-37. [DOI: 10.1016/s1089-3261(02)00064-8] [Cited by in Crossref: 33] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
3 Butler NS, Dandekar AA, Perlman S. Antiviral antibodies are necessary to prevent cytotoxic T-lymphocyte escape in mice infected with a coronavirus. J Virol 2007;81:13291-8. [PMID: 17913802 DOI: 10.1128/JVI.01580-07] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
4 Teixeira R, Marcos LA, Friedman SL. Immunopathogenesis of hepatitis C virus infection and hepatic fibrosis: New insights into antifibrotic therapy in chronic hepatitis C. Hepatology Research 2007;37:579-95. [DOI: 10.1111/j.1872-034x.2007.00085.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
5 Racanelli V, Frassanito MA, Leone P, Brunetti C, Ruggieri S, Dammacco F. Bone marrow of persistently hepatitis C virus-infected individuals accumulates memory CD8+ T cells specific for current and historical viral antigens: a study in patients with benign hematological disorders. J Immunol 2007;179:5387-98. [PMID: 17911625 DOI: 10.4049/jimmunol.179.8.5387] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
6 Vanhommerig JW, Thomas XV, van der Meer JT, Geskus RB, Bruisten SM, Molenkamp R, Prins M, Schinkel J; MOSAIC (MSM Observational Study for Acute Infection with hepatitis C) Study Group. Hepatitis C virus (HCV) antibody dynamics following acute HCV infection and reinfection among HIV-infected men who have sex with men. Clin Infect Dis 2014;59:1678-85. [PMID: 25186590 DOI: 10.1093/cid/ciu695] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 5.3] [Reference Citation Analysis]
7 Ni J, Hembrador E, Di Bisceglie AM, Jacobson IM, Talal AH, Butera D, Rice CM, Chambers TJ, Dustin LB. Accumulation of B lymphocytes with a naive, resting phenotype in a subset of hepatitis C patients. J Immunol 2003;170:3429-39. [PMID: 12626604 DOI: 10.4049/jimmunol.170.6.3429] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 2.6] [Reference Citation Analysis]
8 De Paschale M, Manco MT, Belvisi L, Cagnin D, Cerulli T, Paganini A, Arpino O, Cianflone A, Agrappi C, Mirri P, Clerici P. Evaluation of LIAISON® XL system for HBsAg, and anti-HCV and anti-HIV/Ag p24. J Med Virol 2017;89:489-96. [PMID: 27467710 DOI: 10.1002/jmv.24648] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
9 Wang M, Li JS, Ping Y, Li ZQ, Wang LP, Guo Q, Zhang Z, Yue DL, Wang F, Zhang TF, Islam MS, Zhang Y. The host HLA-A*02 allele is associated with the response to pegylated interferon and ribavirin in patients with chronic hepatitis C virus infection. Arch Virol 2015;160:1043-54. [PMID: 25666200 DOI: 10.1007/s00705-015-2361-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
10 Shata MT, Anthony DD, Carlson NL, Andrus L, Brotman B, Tricoche N, Mccormack P, Prince A. Characterization of the immune response against hepatitis C infection in recovered, and chronically infected chimpanzees. J Viral Hepat 2002;9:400-10. [DOI: 10.1046/j.1365-2893.2002.00373.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 1.6] [Reference Citation Analysis]
11 Kouyoumjian SP, Chemaitelly H, Abu-Raddad LJ. Characterizing hepatitis C virus epidemiology in Egypt: systematic reviews, meta-analyses, and meta-regressions. Sci Rep. 2018;8:1661. [PMID: 29374178 DOI: 10.1038/s41598-017-17936-4] [Cited by in Crossref: 69] [Cited by in F6Publishing: 60] [Article Influence: 17.3] [Reference Citation Analysis]
12 Fu Y, Xia W, Wang Y, Tian L, Pybus OG, Lu L, Nelson K. The seroprevalence of hepatitis C virus (HCV) among 559,890 first-time volunteer blood donors in China reflects regional heterogeneity in HCV prevalence and changes in blood donor recruitment models. Transfusion 2010;50:1505-11. [PMID: 20456675 DOI: 10.1111/j.1537-2995.2010.02616.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
13 Strickland GT, El-kamary SS, Klenerman P, Nicosia A. Hepatitis C vaccine: supply and demand. The Lancet Infectious Diseases 2008;8:379-86. [DOI: 10.1016/s1473-3099(08)70126-9] [Cited by in Crossref: 63] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
14 Liu Y, Shen T, Zhang C, Long L, Duan Z, Lu F. HIV co-infection accelerates decay of humoral responses in spontaneous resolvers of HCV infection. J Viral Hepat 2014;21:690-5. [PMID: 24861885 DOI: 10.1111/jvh.12238] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
15 Shin EC, Sung PS, Park SH. Immune responses and immunopathology in acute and chronic viral hepatitis. Nat Rev Immunol. 2016;16:509-523. [PMID: 27374637 DOI: 10.1038/nri.2016.69] [Cited by in Crossref: 152] [Cited by in F6Publishing: 148] [Article Influence: 25.3] [Reference Citation Analysis]
16 Tillmann HL. Hepatitis C virus infection: when is a cure not a cure? J Infect Dis 2014;209:6-8. [PMID: 24127562 DOI: 10.1093/infdis/jit543] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
17 Rauch A, Gaudieri S, Thio C, Bochud P. Host genetic determinants of spontaneous hepatitis C clearance. Pharmacogenomics 2009;10:1819-37. [DOI: 10.2217/pgs.09.121] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 4.0] [Reference Citation Analysis]
18 Schlaphoff V, Klade CS, Jilma B, Jelovcan SB, Cornberg M, Tauber E, Manns MP, Wedemeyer H; IC41 Study Group. Functional and phenotypic characterization of peptide-vaccine-induced HCV-specific CD8+ T cells in healthy individuals and chronic hepatitis C patients. Vaccine 2007;25:6793-806. [PMID: 17686555 DOI: 10.1016/j.vaccine.2007.06.026] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 2.3] [Reference Citation Analysis]
19 Maylin S, de Verdière NC, Salmona M, Simon F, Delaugerre C. Loss of anti-hepatitis C virus antibodies following therapeutic sustained virological response in a HIV co-infected patient. J Infect Chemother 2014;20:384-6. [PMID: 24613600 DOI: 10.1016/j.jiac.2014.01.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
20 Dustin LB. Reexamining the role of the humoral immune response in control of hepatitis C virus infection. Hepatology 2004;40:756-8. [PMID: 15349916 DOI: 10.1002/hep.20376] [Reference Citation Analysis]
21 Lanford RE, Bigger C, Bassett S, Klimpel G. The chimpanzee model of hepatitis C virus infections. ILAR J 2001;42:117-26. [PMID: 11406714 DOI: 10.1093/ilar.42.2.117] [Cited by in Crossref: 57] [Cited by in F6Publishing: 47] [Article Influence: 2.7] [Reference Citation Analysis]
22 Major ME. Prophylactic and Therapeutic Vaccination against Hepatitis C Virus (HCV): Developments and Future Perspectives. Viruses 2009;1:144-65. [PMID: 21994543 DOI: 10.3390/v1020144] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
23 Long L, Jia M, Fan X, Liang H, Wang J, Zhu L, Xie Z, Shen T. Non-neutralizing epitopes induce robust hepatitis C virus (HCV)-specific antibody-dependent CD56+ natural killer cell responses in chronic HCV-infected patients. Clin Exp Immunol 2017;189:92-102. [PMID: 28317093 DOI: 10.1111/cei.12962] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
24 [DOI: 10.1063/1.5127485] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
25 Morand P, Dutertre N, Minazzi H, Burnichon J, Pernollet M, Baud M, Zarski J, Seigneurin J. Lack of Seroconversion in a Health Care Worker after Polymerase Chain Reaction–Documented Acute Hepatitis C Resulting from a Needlestick Injury. CLIN INFECT DIS 2001;33:727-9. [DOI: 10.1086/322619] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 0.9] [Reference Citation Analysis]
26 Barnaba V. Hepatitis C virus infection: A “liaison a trois” amongst the virus, the host, and chronic low-level inflammation for human survival. Journal of Hepatology 2010;53:752-61. [DOI: 10.1016/j.jhep.2010.06.003] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
27 Arribillaga L, Sarobe P, Arina A, Gorraiz M, Borrás-cuesta F, Ruiz J, Prieto J, Chen L, Melero I, Lasarte JJ. Enhancement of CD4 and CD8 immunity by anti-CD137 (4-1BB) monoclonal antibodies during hepatitis C vaccination with recombinant adenovirus. Vaccine 2005;23:3493-9. [DOI: 10.1016/j.vaccine.2005.02.003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
28 Iken K, Huang L, Bekele H, Schmidt EV, Koziel MJ. Apoptosis of activated CD4+ and CD8+ T cells is enhanced by co-culture with hepatocytes expressing hepatitis C virus (HCV) structural proteins through FasL induction. Virology 2006;346:363-72. [PMID: 16336987 DOI: 10.1016/j.virol.2005.11.017] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 1.8] [Reference Citation Analysis]
29 Chang Q, Wang YK, Zhao Q, Wang CZ, Hu YZ, Wu BY. Th17 cells are increased with severity of liver inflammation in patients with chronic hepatitis C. J Gastroenterol Hepatol. 2012;27:273-278. [PMID: 21592230 DOI: 10.1111/j.1440-1746.2011.06782.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 5.5] [Reference Citation Analysis]
30 Wang M, Wang J, Zhu Y, Xu Z, Yang K, Yang A, Jin B. Cellular immune response to Hantaan virus nucleocapsid protein in the acute phase of hemorrhagic fever with renal syndrome: correlation with disease severity. J Infect Dis 2009;199:188-95. [PMID: 19072554 DOI: 10.1086/595834] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 2.9] [Reference Citation Analysis]
31 He J, Pei X, Xu W, Wang C, Zhang X, Wu J, Zhao W. The relationship between tumor necrosis factor-α polymorphisms and hepatitis C virus infection: a systematic review and meta-analysis. Ren Fail 2011;33:915-22. [PMID: 21851198 DOI: 10.3109/0886022X.2011.605537] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
32 Fytili P, Dalekos GN, Schlaphoff V, Suneetha PV, Sarrazin C, Zauner W, Zachou K, Berg T, Manns MP, Klade CS, Cornberg M, Wedemeyer H. Cross-genotype-reactivity of the immunodominant HCV CD8 T-cell epitope NS3-1073. Vaccine 2008;26:3818-26. [PMID: 18582999 DOI: 10.1016/j.vaccine.2008.05.045] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 2.4] [Reference Citation Analysis]
33 Neumann-haefelin C, Blum H, Chisari F, Thimme R. T cell response in hepatitis C virus infection. Journal of Clinical Virology 2005;32:75-85. [DOI: 10.1016/j.jcv.2004.05.008] [Cited by in Crossref: 87] [Cited by in F6Publishing: 81] [Article Influence: 5.1] [Reference Citation Analysis]
34 Arribillaga L, de Cerio ALD, Sarobe P, Casares N, Gorraiz M, Vales A, Bruna-romero O, Borrás-cuesta F, Paranhos-baccala G, Prieto J, Ruiz J, Lasarte JJ. Vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS3 protein protects against infection with HCV-recombinant vaccinia virus. Vaccine 2002;21:202-10. [DOI: 10.1016/s0264-410x(02)00456-5] [Cited by in Crossref: 45] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
35 Tester I, Smyk-Pearson S, Wang P, Wertheimer A, Yao E, Lewinsohn DM, Tavis JE, Rosen HR. Immune evasion versus recovery after acute hepatitis C virus infection from a shared source. J Exp Med. 2005;201:1725-1731. [PMID: 15939788 DOI: 10.1084/jem.20042284] [Cited by in Crossref: 135] [Cited by in F6Publishing: 130] [Article Influence: 7.9] [Reference Citation Analysis]
36 Macparland SA, Vali B, Ostrowski MA. Immunopathogenesis of HIV/hepatitis C virus coinfection. Future Virology 2011;6:1115-28. [DOI: 10.2217/fvl.11.80] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
37 Zeremski M, Shu MA, Brown Q, Wu Y, Des Jarlais DC, Busch MP, Talal AH, Edlin BR. Hepatitis C virus-specific T-cell immune responses in seronegative injection drug users. J Viral Hepat. 2009;16:10-20. [PMID: 18647233 DOI: 10.1111/j.1365-2893.2008.01016.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 2.4] [Reference Citation Analysis]
38 Elmowalid GA, Qiao M, Jeong SH, Borg BB, Baumert TF, Sapp RK, Hu Z, Murthy K, Liang TJ. Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proc Natl Acad Sci USA. 2007;104:8427-8432. [PMID: 17485666 DOI: 10.1073/pnas.0702162104] [Cited by in Crossref: 129] [Cited by in F6Publishing: 124] [Article Influence: 8.6] [Reference Citation Analysis]
39 Kaźmierczak J, Caraballo Cortes K, Bukowska-Ośko I, Radkowski M. Virus-Specific Cellular Response in Hepatitis C Virus Infection. Arch Immunol Ther Exp (Warsz) 2016;64:101-10. [PMID: 26429740 DOI: 10.1007/s00005-015-0364-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
40 Merat SJ, Molenkamp R, Wagner K, Koekkoek SM, van de Berg D, Yasuda E, Böhne M, Claassen YB, Grady BP, Prins M, Bakker AQ, de Jong MD, Spits H, Schinkel J, Beaumont T. Hepatitis C virus Broadly Neutralizing Monoclonal Antibodies Isolated 25 Years after Spontaneous Clearance. PLoS One 2016;11:e0165047. [PMID: 27776169 DOI: 10.1371/journal.pone.0165047] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.7] [Reference Citation Analysis]
41 Ow MM, Hegazy D, Warshow UM, Cramp ME. Enhanced natural killer cell activity is found in exposed uninfected recipients of hepatitis C-contaminated blood. J Viral Hepat 2018;25:245-53. [PMID: 29063663 DOI: 10.1111/jvh.12810] [Reference Citation Analysis]
42 Dustin LB. Innate and Adaptive Immune Responses in Chronic HCV Infection. Curr Drug Targets 2017;18:826-43. [PMID: 26302811 DOI: 10.2174/1389450116666150825110532] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 6.5] [Reference Citation Analysis]
43 Bakr I, Rekacewicz C, El Hosseiny M, Ismail S, El Daly M, El-Kafrawy S, Esmat G, Hamid MA, Mohamed MK, Fontanet A. Higher clearance of hepatitis C virus infection in females compared with males. Gut 2006;55:1183-7. [PMID: 16434426 DOI: 10.1136/gut.2005.078147] [Cited by in Crossref: 76] [Cited by in F6Publishing: 76] [Article Influence: 4.8] [Reference Citation Analysis]
44 Yutani S, Yamada A, Yoshida K, Takao Y, Tamura M, Komatsu N, Ide T, Tanaka M, Sata M, Itoh K. Phase I clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to respond to interferon-based therapy. Vaccine. 2007;25:7429-7435. [PMID: 17845828 DOI: 10.1016/j.vaccine.2007.08.005] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 2.3] [Reference Citation Analysis]
45 Carreño V, Bartolomé J, Castillo I, Quiroga JA. New perspectives in occult hepatitis C virus infection. World J Gastroenterol 2012; 18(23): 2887-2894 [PMID: 22736911 DOI: 10.3748/wjg.v18.i23.2887] [Cited by in CrossRef: 51] [Cited by in F6Publishing: 49] [Article Influence: 5.1] [Reference Citation Analysis]
46 Shiina M, Kobayashi K, Kobayashi T, Kondo Y, Ueno Y, Shimosegawa T. Dynamics of immature subsets of dendritic cells during antiviral therapy in HLA-A24–positive chronic hepatitis C patients. J Gastroenterol 2006;41:758-64. [DOI: 10.1007/s00535-006-1843-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
47 Monette A, Mouland AJ. T Lymphocytes as Measurable Targets of Protection and Vaccination Against Viral Disorders. Int Rev Cell Mol Biol 2019;342:175-263. [PMID: 30635091 DOI: 10.1016/bs.ircmb.2018.07.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
48 Sánchez-Quijano A, Leal M, Lissen E. [Chronic hepatitis C in patients coinfected by human immunodeficiency virus]. Gastroenterol Hepatol 2002;25:423-31. [PMID: 12069706 DOI: 10.1016/s0210-5705(02)70277-x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
49 Atsukawa M, Nakatsuka K, Kobayashi T, Shimizu M, Tamura H, Harimoto H, Takahashi H, Sakamoto C. Ribavirin downmodulates inducible costimulator on CD4+ T cells and their interleukin-10 secretion to assist in hepatitis C virus clearance. J Gastroenterol Hepatol. 2012;27:823-831. [PMID: 21871023 DOI: 10.1111/j.1440-1746.2011.06882.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
50 Chionne P, Madonna E, Villano U, Tritarelli E, Pisani G, Costantino A, Equestre M, Marcantonio C, Bruni R, Ciccaglione AR. Sensitivity of hepatitis C virus rapid tests in detecting antibodies in general population. Panminerva Med 2020;62:125-30. [PMID: 31692308 DOI: 10.23736/S0031-0808.19.03678-4] [Reference Citation Analysis]
51 Yao ZQ, Eisen-Vandervelde A, Waggoner SN, Cale EM, Hahn YS. Direct binding of hepatitis C virus core to gC1qR on CD4+ and CD8+ T cells leads to impaired activation of Lck and Akt. J Virol. 2004;78:6409-6419. [PMID: 15163734 DOI: 10.1128/jvi.78.12.6409-6419.2004] [Cited by in Crossref: 77] [Cited by in F6Publishing: 43] [Article Influence: 4.3] [Reference Citation Analysis]
52 Langhans B, Braunschweiger I, Arndt S, Schulte W, Satoguina J, Layland LE, Vidovic N, Hoerauf A, Oldenburg J, Sauerbruch T. Core-specific adaptive regulatory T-cells in different outcomes of hepatitis C. Clin Sci (Lond). 2010;119:97-109. [PMID: 20222873 DOI: 10.1042/cs20090661] [Cited by in Crossref: 31] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
53 Boonstra A, Woltman AM, Janssen HL. Immunology of hepatitis B and hepatitis C virus infections. Best Pract Res Clin Gastroenterol. 2008;22:1049-1061. [PMID: 19187866 DOI: 10.1016/j.bpg.2008.11.015] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 2.6] [Reference Citation Analysis]
54 Soguero C, Joo M, Chianese-Bullock KA, Nguyen DT, Tung K, Hahn YS. Hepatitis C virus core protein leads to immune suppression and liver damage in a transgenic murine model. J Virol 2002;76:9345-54. [PMID: 12186917 DOI: 10.1128/jvi.76.18.9345-9354.2002] [Cited by in Crossref: 59] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
55 Major ME, Mihalik K, Puig M, Rehermann B, Nascimbeni M, Rice CM, Feinstone SM. Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge. J Virol. 2002;76:6586-6595. [PMID: 12050371 DOI: 10.1128/jvi.76.13.6586-6595.2002] [Cited by in Crossref: 146] [Cited by in F6Publishing: 58] [Article Influence: 7.3] [Reference Citation Analysis]
56 Ulsenheimer A, Gerlach JT, Gruener NH, Jung MC, Schirren CA, Schraut W, Zachoval R, Pape GR, Diepolder HM. Detection of functionally altered hepatitis C virus-specific CD4 T cells in acute and chronic hepatitis C. Hepatology. 2003;37:1189-1198. [PMID: 12717401 DOI: 10.1053/jhep.2003.50194] [Cited by in Crossref: 171] [Cited by in F6Publishing: 157] [Article Influence: 9.0] [Reference Citation Analysis]
57 Méndez-Lagares G, Lu D, Chen C, Terrault N, Segal MR, Khalili M, Monto A, Shen H, Manos MM, Lanier LL, Ryan JC, McCune JM, Hartigan-O'Connor DJ. Memory T Cell Proliferation before Hepatitis C Virus Therapy Predicts Antiviral Immune Responses and Treatment Success. J Immunol 2018;200:1124-32. [PMID: 29263212 DOI: 10.4049/jimmunol.1701364] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
58 Rosen HR. Hepatitis C pathogenesis: mechanisms of viral clearance and liver injury. Liver Transpl. 2003;9:S35-S43. [PMID: 14586893 DOI: 10.1053/jlts.2003.50253] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 1.8] [Reference Citation Analysis]
59 Lee S, Watson MW, Clark B, Flexman JP, Cheng W, French MA, Price P. Hepatitis C virus genotype and HIV coinfection affect cytokine mRNA levels in unstimulated PBMC but do not shift the T1/T2 balance. Immunol Cell Biol 2006;84:390-5. [PMID: 16834574 DOI: 10.1111/j.1440-1711.2006.01451.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
60 Cashman SB, Marsden BD, Dustin LB. The Humoral Immune Response to HCV: Understanding is Key to Vaccine Development. Front Immunol. 2014;5:550. [PMID: 25426115 DOI: 10.3389/fimmu.2014.00550] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 5.8] [Reference Citation Analysis]
61 Meunier JC, Engle RE, Faulk K, Zhao M, Bartosch B, Alter H, Emerson SU, Cosset FL, Purcell RH, Bukh J. Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1. Proc Natl Acad Sci USA. 2005;102:4560-4565. [PMID: 15767578 DOI: 10.1073/pnas.0501275102] [Cited by in Crossref: 190] [Cited by in F6Publishing: 191] [Article Influence: 11.2] [Reference Citation Analysis]
62 Al-Ayoubi J, Behrendt P, Bremer B, Suneetha PV, Gisa A, Rinker F, Manns MP, Cornberg M, Wedemeyer H, Kraft ARM. Hepatitis E virus ORF 1 induces proliferative and functional T-cell responses in patients with ongoing and resolved hepatitis E. Liver Int 2018;38:266-77. [PMID: 28718943 DOI: 10.1111/liv.13521] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
63 Vergani D, Mieli-vergani G. Viral hepatitis: virus/host interaction. J Gastroenterol Hepatol 2004;19:S307-10. [DOI: 10.1111/j.1440-1746.2004.03693.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
64 Irving WL. Acute hepatitis C virus infection: a neglected disease. Gut. 2006;55:1075-1077. [PMID: 16849345 DOI: 10.1136/gut.2005.085407] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
65 Villani R, Vendemiale G, Serviddio G. Molecular Mechanisms Involved in HCC Recurrence after Direct-Acting Antiviral Therapy. Int J Mol Sci 2018;20:E49. [PMID: 30583555 DOI: 10.3390/ijms20010049] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
66 Thomson M, Nascimbeni M, Havert MB, Major M, Gonzales S, Alter H, Feinstone SM, Murthy KK, Rehermann B, Liang TJ. The clearance of hepatitis C virus infection in chimpanzees may not necessarily correlate with the appearance of acquired immunity. J Virol 2003;77:862-70. [PMID: 12502802 DOI: 10.1128/jvi.77.2.862-870.2003] [Cited by in Crossref: 63] [Cited by in F6Publishing: 29] [Article Influence: 3.3] [Reference Citation Analysis]
67 Heim MH, Thimme R. Innate and adaptive immune responses in HCV infections. J Hepatol. 2014;61:S14-S25. [PMID: 25443342 DOI: 10.1016/j.jhep.2014.06.035] [Cited by in Crossref: 170] [Cited by in F6Publishing: 154] [Article Influence: 21.3] [Reference Citation Analysis]
68 Berzofsky JA, Ahlers JD, Janik J, Morris J, Oh S, Terabe M, Belyakov IM. Progress on new vaccine strategies against chronic viral infections. J Clin Invest. 2004;114:450-462. [PMID: 15314679 DOI: 10.1172/jci200422674] [Cited by in Crossref: 90] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
69 López-Labrador FX, He XS, Berenguer M, Cheung RC, Wright TL, Greenberg HB. The use of class-I HLA tetramers for the detection of hepatitis C virus NS3-specific CD8(+) T cells in patients with chronic infection. J Immunol Methods 2004;287:91-9. [PMID: 15099758 DOI: 10.1016/j.jim.2004.01.023] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
70 Makuria AT, Raghuraman S, Burbelo PD, Cantilena CC, Allison RD, Gibble J, Rehermann B, Alter HJ. The clinical relevance of persistent recombinant immunoblot assay-indeterminate reactions: insights into the natural history of hepatitis C virus infection and implications for donor counseling. Transfusion 2012;52:1940-8. [PMID: 22304422 DOI: 10.1111/j.1537-2995.2011.03524.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
71 Houldsworth A, Metzner M, Hodgkinson A, Shaw S, Kaminski E, Demaine AG, Cramp ME. Haplotype analysis finds linkage disequilibrium in the IL-12 gene in patients with HCV. J Med Virol 2015;87:1207-17. [PMID: 25908236 DOI: 10.1002/jmv.24179] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
72 Semmo N, Barnes E, Taylor C, Kurtz J, Harcourt G, Smith N, Klenerman P. T-cell responses and previous exposure to hepatitis C virus in indeterminate blood donors. Lancet. 2005;365:327-329. [PMID: 15664228 DOI: 10.1016/s0140-6736(05)17787-3] [Cited by in Crossref: 28] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
73 Wedemeyer H, Mizukoshi E, Davis AR, Bennink JR, Rehermann B. Cross-reactivity between hepatitis C virus and Influenza A virus determinant-specific cytotoxic T cells. J Virol. 2001;75:11392-11400. [PMID: 11689620 DOI: 10.1128/jvi.75.23.11392-11400.2001] [Cited by in Crossref: 173] [Cited by in F6Publishing: 88] [Article Influence: 8.2] [Reference Citation Analysis]
74 Gobran ST, Ancuta P, Shoukry NH. A Tale of Two Viruses: Immunological Insights Into HCV/HIV Coinfection. Front Immunol 2021;12:726419. [PMID: 34456931 DOI: 10.3389/fimmu.2021.726419] [Reference Citation Analysis]
75 Klade CS, Wedemeyer H, Berg T, Hinrichsen H, Cholewinska G, Zeuzem S, Blum H, Buschle M, Jelovcan S, Buerger V, Tauber E, Frisch J, Manns MP. Therapeutic Vaccination of Chronic Hepatitis C Nonresponder Patients With the Peptide Vaccine IC41. Gastroenterology 2008;134:1385-1395.e1. [DOI: 10.1053/j.gastro.2008.02.058] [Cited by in Crossref: 110] [Cited by in F6Publishing: 103] [Article Influence: 7.9] [Reference Citation Analysis]
76 Sarobe P, Huarte E, Lasarte JJ, López-Díaz de Cerio A, García N, Borrás-Cuesta F, Prieto J. Characterization of an immunologically conserved epitope from hepatitis C virus E2 glycoprotein recognized by HLA-A2 restricted cytotoxic T lymphocytes. J Hepatol. 2001;34:321-329. [PMID: 11281563 DOI: 10.1016/s0168-8278(00)00018-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
77 Thimme R. T cell immunity to hepatitis C virus: Lessons for a prophylactic vaccine. J Hepatol 2021;74:220-9. [PMID: 33002569 DOI: 10.1016/j.jhep.2020.09.022] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
78 El-attar MM, Ahmed MA, Shehata Hasan M, Aly MA, Nasr AM. Spontaneous viral clearance of chronic HCV infection in Upper Egypt: A community-based study with a 10year follow-up. Arab Journal of Gastroenterology 2010;11:197-201. [DOI: 10.1016/j.ajg.2010.10.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
79 Thomson M, Nascimbeni M, Gonzales S, Murthy KK, Rehermann B, Liang TJ. Emergence of a distinct pattern of viral mutations in chimpanzees infected with a homogeneous inoculum of hepatitis C virus. Gastroenterology 2001;121:1226-33. [PMID: 11677216 DOI: 10.1053/gast.2001.28669] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 2.1] [Reference Citation Analysis]
80 Liao X, Ren H, Zhao P, Zhu S, Cao J, Chen Z, Zhao L, Pan W, Feitelson MA, Qui Z. Efficient Induction of Mouse Immune Responses to Hepatitis C Virus by Viral Core Protein-Carrying Attenuated Salmonella typhimurium. Viral Immunology 2007;20:469-78. [DOI: 10.1089/vim.2006.0112] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
81 El-Shamy A, Sasayama M, Nagano-Fujii M, Sasase N, Imoto S, Kim SR, Hotta H. Prediction of efficient virological response to pegylated interferon/ribavirin combination therapy by NS5A sequences of hepatitis C virus and anti-NS5A antibodies in pre-treatment sera. Microbiol Immunol. 2007;51:471-482. [PMID: 17446688 DOI: 10.1111/j.1348-0421.2007.tb03922.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.4] [Reference Citation Analysis]
82 Roger P, Chaillou S, Breittmayer J, Dahman M, St. Paul M, Chevallier P, Benzaken S, Ticchioni M, Bernard A, Dellamonica P, Tran A. Intrahepatic CD4+ T-Cell Apoptosis is Related to METAVIR Score in Patients With Chronic Hepatitis C Virus. Scand J Immunol 2005;62:168-75. [DOI: 10.1111/j.1365-3083.2005.01648.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
83 Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med. 2001;194:1395-1406. [PMID: 11714747 DOI: 10.1084/jem.194.10.1395] [Cited by in Crossref: 862] [Cited by in F6Publishing: 836] [Article Influence: 41.0] [Reference Citation Analysis]
84 Lloyd AR, Jagger E, Post JJ, Crooks LA, Rawlinson WD, Hahn YS, Ffrench RA. Host and viral factors in the immunopathogenesis of primary hepatitis C virus infection. Immunol Cell Biol 2007;85:24-32. [PMID: 17130897 DOI: 10.1038/sj.icb.7100010] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 2.5] [Reference Citation Analysis]
85 Ip PP, Boerma A, Regts J, Meijerhof T, Wilschut J, Nijman HW, Daemen T. Alphavirus-based vaccines encoding nonstructural proteins of hepatitis C virus induce robust and protective T-cell responses. Mol Ther 2014;22:881-90. [PMID: 24370701 DOI: 10.1038/mt.2013.287] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
86 Nascimbeni M, Mizukoshi E, Bosmann M, Major ME, Mihalik K, Rice CM, Feinstone SM, Rehermann B. Kinetics of CD4+ and CD8+ memory T-cell responses during hepatitis C virus rechallenge of previously recovered chimpanzees. J Virol. 2003;77:4781-4793. [PMID: 12663785 DOI: 10.1128/jvi.77.8.4781-4793.2003] [Cited by in Crossref: 144] [Cited by in F6Publishing: 71] [Article Influence: 7.6] [Reference Citation Analysis]
87 Sacchi A, Tumino N, Turchi F, Refolo G, Fimia G, Ciccosanti F, Montalbano M, Lionetti R, Taibi C, D'Offizi G, Casetti R, Bordoni V, Cimini E, Martini F, Agrati C. Dendritic cells activation is associated with sustained virological response to telaprevir treatment of HCV-infected patients. Clin Immunol 2017;183:82-90. [PMID: 28736275 DOI: 10.1016/j.clim.2017.07.017] [Reference Citation Analysis]
88 Mehta SH, Cox A, Hoover DR, Wang XH, Mao Q, Ray S, Strathdee SA, Vlahov D, Thomas DL. Protection against persistence of hepatitis C. Lancet. 2002;359:1478-1483. [PMID: 11988247 DOI: 10.1016/s0140-6736(02)08435-0] [Cited by in Crossref: 319] [Cited by in F6Publishing: 132] [Article Influence: 16.0] [Reference Citation Analysis]
89 Carreño García V, Nebreda JB, Aguilar IC, Quiroga Estévez JA. [Occult hepatitis C virus infection]. Enferm Infecc Microbiol Clin 2011;29 Suppl 3:14-9. [PMID: 21458706 DOI: 10.1016/S0213-005X(11)70022-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
90 Shiina M, Rehermann B. Hepatitis C vaccines: Inducing and challenging memory T cells. Hepatology. 2006;43:1395-1398. [PMID: 16729320 DOI: 10.1002/hep.21210] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
91 Schvoerer E, Navas MC, Thumann C, Fuchs A, Meyer N, Habersetzer F, Stoll-Keller F. Production of interleukin-18 and interleukin-12 in patients suffering from chronic hepatitis C virus infection before antiviral therapy. J Med Virol. 2003;70:588-593. [PMID: 12794721 DOI: 10.1002/jmv.10434] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.0] [Reference Citation Analysis]
92 Kaplan DE. Immunopathogenesis of Hepatitis C Virus Infection. Gastroenterol Clin North Am 2015;44:735-60. [PMID: 26600217 DOI: 10.1016/j.gtc.2015.07.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
93 Ebinuma H, Nakamoto N, Li Y, Price DA, Gostick E, Levine BL, Tobias J, Kwok WW, Chang KM. Identification and in vitro expansion of functional antigen-specific CD25+ FoxP3+ regulatory T cells in hepatitis C virus infection. J Virol 2008;82:5043-53. [PMID: 18337568 DOI: 10.1128/JVI.01548-07] [Cited by in Crossref: 127] [Cited by in F6Publishing: 68] [Article Influence: 9.1] [Reference Citation Analysis]
94 Zeremski M, Makeyeva J, Arasteh K, Des Jarlais DC, Talal AH. Hepatitis C virus-specific immune responses in noninjecting drug users. J Viral Hepat 2012;19:554-9. [PMID: 22762139 DOI: 10.1111/j.1365-2893.2011.01573.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
95 Casiraghi MA, De Paschale M, Romanò L, Biffi R, Assi A, Binelli G, Zanetti AR. Long-term outcome (35 years) of hepatitis C after acquisition of infection through mini transfusions of blood given at birth. Hepatology. 2004;39:90-96. [PMID: 14752827 DOI: 10.1002/hep.20030] [Cited by in Crossref: 111] [Cited by in F6Publishing: 93] [Article Influence: 6.2] [Reference Citation Analysis]
96 Shoukry NH, Sidney J, Sette A, Walker CM. Conserved hierarchy of helper T cell responses in a chimpanzee during primary and secondary hepatitis C virus infections. J Immunol. 2004;172:483-492. [PMID: 14688358 DOI: 10.4049/jimmunol.172.1.483] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 2.6] [Reference Citation Analysis]
97 Bertoletti A, Ferrari C. Kinetics of the immune response during HBV and HCV infection. Hepatology. 2003;38:4-13. [PMID: 12829979 DOI: 10.1053/jhep.2003.50310] [Cited by in Crossref: 160] [Cited by in F6Publishing: 168] [Article Influence: 8.4] [Reference Citation Analysis]
98 Herkel J, Jagemann B, Wiegard C, Lazaro JF, Lueth S, Kanzler S, Blessing M, Schmitt E, Lohse AW. MHC class II-expressing hepatocytes function as antigen-presenting cells and activate specific CD4 T lymphocyutes. Hepatology. 2003;37:1079-1085. [PMID: 12717388 DOI: 10.1053/jhep.2003.50191] [Cited by in Crossref: 92] [Cited by in F6Publishing: 90] [Article Influence: 4.8] [Reference Citation Analysis]
99 Zhu F, Eckels DD. Functionally distinct helper T-cell epitopes of HCV and their role in modulation of NS3-specific, CD8+/tetramer positive CTL. Human Immunology 2002;63:710-8. [DOI: 10.1016/s0198-8859(02)00430-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
100 Riche H, Chiara Y, Jaboulay JM. [Clinical outcome in the surgery of intracranial aneurysms: 229 cases]. Agressologie. 1990;31:271-273. [PMID: 2288341 DOI: 10.1016/j.jpeds.2012.06.057] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 0.5] [Reference Citation Analysis]
101 Nelson DR, Tu Z, Soldevila-Pico C, Abdelmalek M, Zhu H, Xu YL, Cabrera R, Liu C, Davis GL. Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. Hepatology 2003;38:859-68. [PMID: 14512873 DOI: 10.1053/jhep.2003.50427] [Cited by in Crossref: 77] [Cited by in F6Publishing: 39] [Article Influence: 4.1] [Reference Citation Analysis]
102 Tanner MS. Mechanisms of liver injury relevant to pediatric hepatology. Crit Rev Clin Lab Sci. 2002;39:1-61. [PMID: 11890207 DOI: 10.1080/10408360290795439] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
103 Manigold T, Shin EC, Mizukoshi E, Mihalik K, Murthy KK, Rice CM, Piccirillo CA, Rehermann B. Foxp3+CD4+CD25+ T cells control virus-specific memory T cells in chimpanzees that recovered from hepatitis C. Blood. 2006;107:4424-4432. [PMID: 16478885 DOI: 10.1182/blood-2005-09-3903] [Cited by in Crossref: 91] [Cited by in F6Publishing: 78] [Article Influence: 5.7] [Reference Citation Analysis]
104 Wandeler G, Gsponer T, Bregenzer A, Günthard HF, Clerc O, Calmy A, Stöckle M, Bernasconi E, Furrer H, Rauch A. Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic. Clin Infect Dis. 2012;55:1408-1416. [PMID: 22893583 DOI: 10.1093/cid/cis694] [Cited by in Crossref: 179] [Cited by in F6Publishing: 173] [Article Influence: 17.9] [Reference Citation Analysis]
105 Hitziger T, Schmidt M, Schottstedt V, Hennig H, Schumann A, Ross S, Lu M, Seifried E, Roggendorf M. Cellular immune response to hepatitis C virus (HCV) in nonviremic blood donors with indeterminate anti-HCV reactivity. Transfusion 2009;49:1306-13. [PMID: 19309471 DOI: 10.1111/j.1537-2995.2009.02113.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
106 Bukh J. A critical role for the chimpanzee model in the study of hepatitis C. Hepatology 2004;39:1469-75. [DOI: 10.1002/hep.20268] [Cited by in Crossref: 129] [Cited by in F6Publishing: 115] [Article Influence: 7.2] [Reference Citation Analysis]
107 Mazouz S, Boisvert M, Abdel-Hakeem MS, Khedr O, Bruneau J, Shoukry NH. Expansion of Unique Hepatitis C Virus-Specific Public CD8+ T Cell Clonotypes during Acute Infection and Reinfection. J Immunol 2021;207:1180-93. [PMID: 34341170 DOI: 10.4049/jimmunol.2001386] [Reference Citation Analysis]
108 Sugimoto K, Stadanlick J, Ikeda F, Brensinger C, Furth EE, Alter HJ, Chang KM. Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response. Hepatology. 2003;37:590-599. [PMID: 12601357 DOI: 10.1053/jhep.2003.50103] [Cited by in Crossref: 84] [Cited by in F6Publishing: 78] [Article Influence: 4.4] [Reference Citation Analysis]
109 Stapleton JT, Foung S, Muerhoff AS, Bukh J, Simmonds P. The GB viruses: a review and proposed classification of GBV-A, GBV-C (HGV), and GBV-D in genus Pegivirus within the family Flaviviridae. J Gen Virol. 2011;92:233-246. [PMID: 21084497 DOI: 10.1099/vir.0.027490-0] [Cited by in Crossref: 182] [Cited by in F6Publishing: 175] [Article Influence: 15.2] [Reference Citation Analysis]
110 Hardikar W. Hepatitis C in childhood. J Gastroenterol Hepatol 2002;17:476-81. [DOI: 10.1046/j.1440-1746.2002.02731.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
111 Kamal SM, Kassim SK, Ahmed AI, Mahmoud S, Bahnasy KA, Hafez TA, Aziz IA, Fathelbab IF, Mansour HM. Host and Viral Determinants of the Outcome of Exposure to HCV Infection Genotype 4: A Large Longitudinal Study. American Journal of Gastroenterology 2014;109:199-211. [DOI: 10.1038/ajg.2013.427] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
112 Qiu Q, Wang RY, Jiao X, Jin B, Sugauchi F, Grandinetti T, Alter HJ, Shih JW. Induction of multispecific Th-1 type immune response against HCV in mice by protein immunization using CpG and Montanide ISA 720 as adjuvants. Vaccine. 2008;26:5527-5534. [PMID: 18675871 DOI: 10.1016/j.vaccine.2008.07.034] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
113 Li Q, Dong C, Wang J, Che Y, Jiang L, Wang J, Sun M, Wang L, Huang J, Ren D. Induction of hepatitis C virus-specific humoral and cellular immune responses in mice and rhesus by artificial multiple epitopes sequence. Viral Immunol. 2003;16:321-333. [PMID: 14583147 DOI: 10.1089/088282403322396127] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
114 Danta M, Semmo N, Fabris P, Brown D, Pybus OG, Sabin CA, Bhagani S, Emery VC, Dusheiko GM, Klenerman P. Impact of HIV on host-virus interactions during early hepatitis C virus infection. J Infect Dis. 2008;197:1558-1566. [PMID: 18419344 DOI: 10.1086/587843] [Cited by in Crossref: 76] [Cited by in F6Publishing: 71] [Article Influence: 5.4] [Reference Citation Analysis]
115 Rehermann B, Thimme R. Insights From Antiviral Therapy Into Immune Responses to Hepatitis B and C Virus Infection. Gastroenterology 2019;156:369-83. [PMID: 30267712 DOI: 10.1053/j.gastro.2018.08.061] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 12.5] [Reference Citation Analysis]
116 Gaudieri S, Rauch A, Park LP, Freitas E, Herrmann S, Jeffrey G, Cheng W, Pfafferott K, Naidoo K, Chapman R. Evidence of viral adaptation to HLA class I-restricted immune pressure in chronic hepatitis C virus infection. J Virol. 2006;80:11094-11104. [PMID: 17071929 DOI: 10.1128/jvi.00912-06] [Cited by in Crossref: 76] [Cited by in F6Publishing: 58] [Article Influence: 4.8] [Reference Citation Analysis]
117 Jeong HG, Kim JY. Induction of inducible nitric oxide synthase expression by 18beta-glycyrrhetinic acid in macrophages. FEBS Lett 2002;513:208-12. [PMID: 11904152 DOI: 10.1016/s0014-5793(02)02311-6] [Cited by in Crossref: 40] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
118 Pham TN, Michalak TI. Occult persistence and lymphotropism of hepatitis C virus infection. World J Gastroenterol 2008; 14(18): 2789-2793 [PMID: 18473399 DOI: 10.3748/wjg.14.2789] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
119 Carreño V, Bartolomé J, Castillo I, Quiroga JA. Occult hepatitis B virus and hepatitis C virus infections. Rev Med Virol 2008;18:139-57. [PMID: 18265423 DOI: 10.1002/rmv.569] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 3.0] [Reference Citation Analysis]
120 Lavillette D, Morice Y, Germanidis G, Donot P, Soulier A, Pagkalos E, Sakellariou G, Intrator L, Bartosch B, Pawlotsky JM. Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. J Virol. 2005;79:6023-6034. [PMID: 15857988 DOI: 10.1128/jvi.79.10.6023-6034.2005] [Cited by in Crossref: 201] [Cited by in F6Publishing: 97] [Article Influence: 11.8] [Reference Citation Analysis]
121 Alatrakchi N, Graham CS, van der Vliet HJ, Sherman KE, Exley MA, Koziel MJ. Hepatitis C virus (HCV)-specific CD8+ cells produce transforming growth factor beta that can suppress HCV-specific T-cell responses. J Virol. 2007;81:5882-5892. [PMID: 17376924 DOI: 10.1128/jvi.02202-06] [Cited by in Crossref: 79] [Cited by in F6Publishing: 43] [Article Influence: 5.3] [Reference Citation Analysis]
122 Yachimski P, Chung RT. Update on Hepatitis B and C Coinfection in HIV. Curr Infect Dis Rep. 2005;7:299-308. [PMID: 15963332 DOI: 10.1007/s11908-005-0063-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
123 Welker M, Zeuzem S. Occult hepatitis C: How convincing are the current data? Hepatology 2009;49:665-75. [DOI: 10.1002/hep.22706] [Cited by in Crossref: 66] [Cited by in F6Publishing: 67] [Article Influence: 4.7] [Reference Citation Analysis]
124 Berenguer M, López-Labrador FX, Wright TL. Hepatitis C and liver transplantation. J Hepatol. 2001;35:666-678. [PMID: 11690716 DOI: 10.1016/s0168-8278(01)00179-9] [Cited by in Crossref: 222] [Cited by in F6Publishing: 45] [Article Influence: 11.1] [Reference Citation Analysis]
125 Kefalakes H, Jochum C, Hilgard G, Kahraman A, Bohrer AM, El Hindy N, Heinemann FM, Verheyen J, Gerken G, Roggendorf M, Timm J. Decades after recovery from hepatitis B and HBsAg clearance the CD8+ T cell response against HBV core is nearly undetectable. Journal of Hepatology 2015;63:13-9. [DOI: 10.1016/j.jhep.2015.01.030] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
126 Chua BY, Eriksson EM, Brown LE, Zeng W, Gowans EJ, Torresi J, Jackson DC. A self-adjuvanting lipopeptide-based vaccine candidate for the treatment of hepatitis C virus infection. Vaccine 2008;26:4866-75. [PMID: 18455278 DOI: 10.1016/j.vaccine.2008.03.032] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 3.1] [Reference Citation Analysis]
127 Stevenson FK, Rosenberg W. DNA vaccination: a potential weapon against infection and cancer: DNA vaccination: a potential weapon against infection and cancer. Vox Sanguinis 2001;80:12-8. [DOI: 10.1046/j.1423-0410.2001.00009.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
128 Mueller T, Mas-Marques A, Sarrazin C, Wiese M, Halangk J, Witt H, Ahlenstiel G, Spengler U, Goebel U, Wiedenmann B, Schreier E, Berg T. Influence of interleukin 12B (IL12B) polymorphisms on spontaneous and treatment-induced recovery from hepatitis C virus infection. J Hepatol 2004;41:652-8. [PMID: 15464247 DOI: 10.1016/j.jhep.2004.06.021] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 2.3] [Reference Citation Analysis]
129 Echeverría N, Comas V, Aldunate F, Perbolianachis P, Moreno P, Cristina J. In the era of rapid mRNA-based vaccines: Why is there no effective hepatitis C virus vaccine yet? . World J Hepatol 2021; 13(10): 1234-1268 [PMID: 34786164 DOI: 10.4254/wjh.v13.i10.1234] [Reference Citation Analysis]
130 Strasak AM, Kim AY, Lauer GM, de Sousa PS, Ginuino CF, Fernandes CA, Velloso CE, de Almeida AJ, de Oliveira JM, Yoshida CF, Schulze zur Wiesch J, Paranhos-Baccalá G, Lang S, Brant LJ, Ulmer H, Strohmaier S, Kaltenbach L, Lampe E, Lewis-Ximenez LL. Antibody dynamics and spontaneous viral clearance in patients with acute hepatitis C infection in Rio de Janeiro, Brazil. BMC Infect Dis 2011;11:15. [PMID: 21226945 DOI: 10.1186/1471-2334-11-15] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
131 Aboul-Ata AA, Vitti A, Nuzzaci M, El-Attar AK, Piazzolla G, Tortorella C, Harandi AM, Olson O, Wright SA, Piazzolla P. Plant-based vaccines: novel and low-cost possible route for Mediterranean innovative vaccination strategies. Adv Virus Res 2014;89:1-37. [PMID: 24751193 DOI: 10.1016/B978-0-12-800172-1.00001-X] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
132 Zhang L, Miao L, Fu HC, Zhao GZ, Feng GH, Dou XG. Significance of changes in serum IL-18 and IL-1β levels in patients with chronic hepatitis C. Shijie Huaren Xiaohua Zazhi 2009; 17(20): 2105-2111 [DOI: 10.11569/wcjd.v17.i20.2105] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
133 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu.; European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018;69:461-511. [PMID: 29650333 DOI: 10.1016/j.jhep.2018.03.026] [Cited by in Crossref: 905] [Cited by in F6Publishing: 751] [Article Influence: 226.3] [Reference Citation Analysis]
134 Himoudi N, Abraham JD, Fournillier A, Lone YC, Joubert A, Op De Beeck A, Freida D, Lemonnier F, Kieny MP, Inchauspé G. Comparative vaccine studies in HLA-A2.1-transgenic mice reveal a clustered organization of epitopes presented in hepatitis C virus natural infection. J Virol 2002;76:12735-46. [PMID: 12438599 DOI: 10.1128/jvi.76.24.12735-12746.2002] [Cited by in Crossref: 31] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
135 Kim AY, Chung RT. HIV and hepatitis C virus coinfection update. Curr hepatitis rep 2004;3:83-90. [DOI: 10.1007/s11901-004-0014-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
136 Lukens JR, Dolina JS, Kim TS, Tacke RS, Hahn YS. Liver is able to activate naïve CD8+ T cells with dysfunctional anti-viral activity in the murine system. PLoS One 2009;4:e7619. [PMID: 19876399 DOI: 10.1371/journal.pone.0007619] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
137 Quiroga JA, Castillo I, Llorente S, Bartolomé J, Barril G, Carreño V. Identification of serologically silent occult hepatitis C virus infection by detecting immunoglobulin G antibody to a dominant HCV core peptide epitope. J Hepatol 2009;50:256-63. [PMID: 19070391 DOI: 10.1016/j.jhep.2008.08.021] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
138 Ragab L, Helal S, Zaghloul N, El-raziky M, Afifi R, Musallam KM, Taher AT. Clinicovirologic analysis of hepatitis C infection in transfusion-dependent β-thalassemia major children. International Journal of Laboratory Hematology 2010;32:184-90. [DOI: 10.1111/j.1751-553x.2009.01155.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
139 Wietzke-Braun P, Mänhardt LB, Rosenberger A, Uy A, Ramadori G, Mihm S. Spontaneous elimination of hepatitis C virus infection: A retrospective study on demographic, clinical, and serological correlates. World J Gastroenterol 2007; 13(31): 4224-4229 [PMID: 17696252 DOI: 10.3748/wjg.v13.i31.4224] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
140 Jovanović M, Konstantinović L, Katić V, Cirić S, Kostić V, Jovanović B. [Histopathologic and immunocytochemical changes in the liver in patients with chronic hepatitis C]. Vojnosanit Pregl 2004;61:29-34. [PMID: 15022386 DOI: 10.2298/vsp0401029j] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
141 Hanada K, Tanaka Y, Mizokami M, Gojobori T, Alter HJ. A reduction in selective immune pressure during the course of chronic hepatitis C correlates with diminished biochemical evidence of hepatic inflammation. Virology 2007;361:27-33. [DOI: 10.1016/j.virol.2006.10.041] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
142 Kubitschke A, Bahr MJ, Aslan N, Bader C, Tillmann HL, Sarrazin C, Greten T, Wiegand J, Manns MP, Wedemeyer H. Induction of hepatitis C virus (HCV)-specific T cells by needle stick injury in the absence of HCV-viraemia. Eur J Clin Invest. 2007;37:54-64. [PMID: 17181568 DOI: 10.1111/j.1365-2362.2007.01753.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 1.9] [Reference Citation Analysis]
143 Rosen HR, Miner C, Sasaki AW, Lewinsohn DM, Conrad AJ, Bakke A, Bouwer HG, Hinrichs DJ. Frequencies of HCV-specific effector CD4+ T cells by flow cytometry: correlation with clinical disease stages. Hepatology. 2002;35:190-198. [PMID: 11786976 DOI: 10.1053/jhep.2002.30293] [Cited by in Crossref: 133] [Cited by in F6Publishing: 130] [Article Influence: 6.7] [Reference Citation Analysis]
144 Zhang Y, Liu Y, Zhao Y, Shi L, Ma L, Yan H, Wu H, Wei L, Dong T, Chen X. Hepatitis C virus nonstructural protein specific T cells are associated with virological responses to combination therapy in chronic HCV patients. Liver Int 2012;32:102-9. [PMID: 22098382 DOI: 10.1111/j.1478-3231.2011.02652.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
145 Thurairajah PH, Hegazy D, Chokshi S, Shaw S, Demaine A, Kaminski ER, Naoumov NV, Cramp ME. Hepatitis C virus (HCV)--specific T cell responses in injection drug users with apparent resistance to HCV infection. J Infect Dis 2008;198:1749-55. [PMID: 18959498 DOI: 10.1086/593337] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 3.2] [Reference Citation Analysis]
146 Bes M, Sauleda S, Campos-varela I, Rodriguez-frias F, Casamitjana N, Homs M, Piron M, Quer J, Tabernero D, Guardia J, Puig L, Esteban JI. IL28B genetic variation and hepatitis C virus-specific CD4 + T-cell responses in anti-HCV-positive blood donors: IL28B and HCV-specific T-cell responses. Journal of Viral Hepatitis 2012;19:867-71. [DOI: 10.1111/j.1365-2893.2012.01631.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
147 Coto-Llerena M, Lepore M, Spagnuolo J, Di Blasi D, Calabrese D, Suslov A, Bantug G, Duong FH, Terracciano LM, De Libero G, Heim MH. Interferon lambda 4 can directly activate human CD19+ B cells and CD8+ T cells. Life Sci Alliance 2021;4:e201900612. [PMID: 33158978 DOI: 10.26508/lsa.201900612] [Reference Citation Analysis]
148 Kim AY, Schulze zur Wiesch J, Kuntzen T, Timm J, Kaufmann DE, Duncan JE, Jones AM, Wurcel AG, Davis BT, Gandhi RT. Impaired hepatitis C virus-specific T cell responses and recurrent hepatitis C virus in HIV coinfection. PLoS Med. 2006;3:e492. [PMID: 17194190 DOI: 10.1371/journal.pmed.0030492] [Cited by in Crossref: 65] [Cited by in F6Publishing: 62] [Article Influence: 4.3] [Reference Citation Analysis]
149 Crux NB, Elahi S. Human Leukocyte Antigen (HLA) and Immune Regulation: How Do Classical and Non-Classical HLA Alleles Modulate Immune Response to Human Immunodeficiency Virus and Hepatitis C Virus Infections? Front Immunol. 2017;8:832. [PMID: 28769934 DOI: 10.3389/fimmu.2017.00832] [Cited by in Crossref: 68] [Cited by in F6Publishing: 61] [Article Influence: 13.6] [Reference Citation Analysis]
150 Georgel P, Schuster C, Zeisel MB, Stoll-Keller F, Berg T, Bahram S, Baumert TF. Virus-host interactions in hepatitis C virus infection: implications for molecular pathogenesis and antiviral strategies. Trends Mol Med. 2010;16:277-286. [PMID: 20537953 DOI: 10.1016/j.molmed.2010.04.003] [Cited by in Crossref: 50] [Cited by in F6Publishing: 50] [Article Influence: 4.2] [Reference Citation Analysis]
151 Lukens JR, Cruise MW, Lassen MG, Hahn YS. Blockade of PD-1/B7-H1 interaction restores effector CD8+ T cell responses in a hepatitis C virus core murine model. J Immunol 2008;180:4875-84. [PMID: 18354211 DOI: 10.4049/jimmunol.180.7.4875] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 3.9] [Reference Citation Analysis]
152 Sengupta S, Siliciano RF. Targeting the Latent Reservoir for HIV-1. Immunity 2018;48:872-95. [PMID: 29768175 DOI: 10.1016/j.immuni.2018.04.030] [Cited by in Crossref: 150] [Cited by in F6Publishing: 139] [Article Influence: 50.0] [Reference Citation Analysis]
153 Wong DK, Dudley DD, Dohrenwend PB, Lauer GM, Chung RT, Thomas DL, Walker BD. Detection of diverse hepatitis C virus (HCV)-specific cytotoxic T lymphocytes in peripheral blood of infected persons by screening for responses to all translated proteins of HCV. J Virol. 2001;75:1229-1235. [PMID: 11152496 DOI: 10.1128/jvi.75.3.1229-1235.2001] [Cited by in Crossref: 54] [Cited by in F6Publishing: 27] [Article Influence: 2.6] [Reference Citation Analysis]
154 Claassen MA, de Knegt RJ, Tilanus HW, Janssen HL, Boonstra A. Abundant numbers of regulatory T cells localize to the liver of chronic hepatitis C infected patients and limit the extent of fibrosis. J Hepatol. 2010;52:315-321. [PMID: 20129690 DOI: 10.1016/j.jhep.2009.12.013] [Cited by in Crossref: 91] [Cited by in F6Publishing: 94] [Article Influence: 7.0] [Reference Citation Analysis]
155 Della Bella S, Riva A, Tanzi E, Nicola S, Amendola A, Vecchi L, Nebbia G, Longhi R, Zanetti AR, Villa ML. Hepatitis C virus-specific reactivity of CD4+-lymphocytes in children born from HCV-infected women. J Hepatol 2005;43:394-402. [PMID: 16023248 DOI: 10.1016/j.jhep.2005.03.022] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 1.4] [Reference Citation Analysis]
156 Jeong SH, Qiao M, Nascimbeni M, Hu Z, Rehermann B, Murthy K, Liang TJ. Immunization with hepatitis C virus-like particles induces humoral and cellular immune responses in nonhuman primates. J Virol. 2004;78:6995-7003. [PMID: 15194776 DOI: 10.1128/jvi.78.13.6995-7003.2004] [Cited by in Crossref: 87] [Cited by in F6Publishing: 37] [Article Influence: 4.8] [Reference Citation Analysis]
157 Park SH, Shin EC, Capone S, Caggiari L, De Re V, Nicosia A, Folgori A, Rehermann B. Successful vaccination induces multifunctional memory T-cell precursors associated with early control of hepatitis C virus. Gastroenterology. 2012;143:1048-60.e4. [PMID: 22705008 DOI: 10.1053/j.gastro.2012.06.005] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 5.1] [Reference Citation Analysis]
158 Persaud D, Zhou Y, Siliciano JM, Siliciano RF. Latency in human immunodeficiency virus type 1 infection: no easy answers. J Virol 2003;77:1659-65. [PMID: 12525599 DOI: 10.1128/jvi.77.3.1659-1665.2003] [Cited by in Crossref: 117] [Cited by in F6Publishing: 58] [Article Influence: 6.2] [Reference Citation Analysis]
159 Kulkarni SP, Sharma M, Tripathy AS. Antibody and Memory B Cell Responses in Hepatitis E Recovered Individuals, 1-30 Years Post Hepatitis E Virus Infection. Sci Rep 2019;9:4090. [PMID: 30858463 DOI: 10.1038/s41598-019-40603-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
160 El-gogo S, Staib C, Lasarte JJ, Sutter G, Adler H. Protective vaccination with hepatitis C virus NS3 but not core antigen in a novel mouse challenge model. J Gene Med 2008;10:177-86. [DOI: 10.1002/jgm.1144] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
161 Nanda S, Havert MB, Calderón GM, Thomson M, Jacobson C, Kastner D, Liang TJ. Hepatic transcriptome analysis of hepatitis C virus infection in chimpanzees defines unique gene expression patterns associated with viral clearance. PLoS One 2008;3:e3442. [PMID: 18927617 DOI: 10.1371/journal.pone.0003442] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
162 Simmons R, Sharp C, Sims S, Kloverpris H, Goulder P, Simmonds P, Bowness P, Klenerman P. High frequency, sustained T cell responses to PARV4 suggest viral persistence in vivo. J Infect Dis 2011;203:1378-87. [PMID: 21502079 DOI: 10.1093/infdis/jir036] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
163 Yao ZQ, King E, Prayther D, Yin D, Moorman J. T cell dysfunction by hepatitis C virus core protein involves PD-1/PDL-1 signaling. Viral Immunol. 2007;20:276-287. [PMID: 17603844 DOI: 10.1089/vim.2006.0096] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 3.7] [Reference Citation Analysis]
164 Szabo G, Aloman C, Polyak SJ, Weinman SA, Wands J, Zakhari S. Hepatitis C infection and alcohol use: A dangerous mix for the liver and antiviral immunity. Alcohol Clin Exp Res 2006;30:709-19. [PMID: 16573590 DOI: 10.1111/j.1530-0277.2006.00083.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 2.9] [Reference Citation Analysis]
165 Syder AJ, Lee H, Zeisel MB, Grove J, Soulier E, Macdonald J, Chow S, Chang J, Baumert TF, McKeating JA. Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors. J Hepatol. 2011;54:48-55. [PMID: 20932595 DOI: 10.1016/j.jhep.2010.06.024] [Cited by in Crossref: 99] [Cited by in F6Publishing: 96] [Article Influence: 8.3] [Reference Citation Analysis]
166 Zhang YH, Zhao Y, Rajapaksa US, Lawrence TM, Peng YC, Liu J, Xu K, Hu K, Qin L, Liu N, Sun H, Yan HP, Repapi E, Rowland-Jones S, Thimme R, McKeating JA, Dong T. A Comprehensive Analysis of the Impact of HIV on HCV Immune Responses and Its Association with Liver Disease Progression in a Unique Plasma Donor Cohort. PLoS One 2016;11:e0158037. [PMID: 27455208 DOI: 10.1371/journal.pone.0158037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
167 Mondelli MU, Varchetta S, Negro F. Hepatitis C. In: Gershwin ME, Vierling JM, Manns MP, editors. Liver Immunology. Cham: Springer International Publishing; 2014. pp. 207-30. [DOI: 10.1007/978-3-319-02096-9_15] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
168 Quer J, Martell M, Rodriguez F, Bosch A, Jardi R, Buti M, Esteban J. The Impact of Rapid Evolution of Hepatitis Viruses. Origin and Evolution of Viruses. Elsevier; 2008. pp. 303-49. [DOI: 10.1016/b978-0-12-374153-0.00015-1] [Cited by in Crossref: 6] [Article Influence: 0.4] [Reference Citation Analysis]
169 Polakos NK, Drane D, Cox J, Ng P, Selby MJ, Chien D, O'Hagan DT, Houghton M, Paliard X. Characterization of hepatitis C virus core-specific immune responses primed in rhesus macaques by a nonclassical ISCOM vaccine. J immunol. 2001;166:3589-3598. [PMID: 11207320 DOI: 10.4049/jimmunol.166.5.3589] [Cited by in Crossref: 76] [Cited by in F6Publishing: 67] [Article Influence: 3.6] [Reference Citation Analysis]
170 Murray AJ, Kwon KJ, Farber DL, Siliciano RF. The Latent Reservoir for HIV-1: How Immunologic Memory and Clonal Expansion Contribute to HIV-1 Persistence. J Immunol 2016;197:407-17. [PMID: 27382129 DOI: 10.4049/jimmunol.1600343] [Cited by in Crossref: 92] [Cited by in F6Publishing: 82] [Article Influence: 18.4] [Reference Citation Analysis]
171 Kim JY, Won JE, Jeong SH, Park SJ, Hwang SG, Kang SK, Bae SH, Kim YS, Lee HC. Acute hepatitis C in Korea: different modes of infection, high rate of spontaneous recovery, and low rate of seroconversion. J Med Virol. 2011;83:1195-1202. [PMID: 21567423 DOI: 10.1002/jmv.22100] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
172 Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest 2009;119:1745-54. [PMID: 19587449 DOI: 10.1172/JCI39133] [Cited by in Crossref: 379] [Cited by in F6Publishing: 226] [Article Influence: 29.2] [Reference Citation Analysis]
173 Heydtmann M, Shields P, Mccaughan G, Adams D. Cytokines and chemokines in the immune response to hepatitis C infection: . Current Opinion in Infectious Diseases 2001;14:279-87. [DOI: 10.1097/00001432-200106000-00006] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 1.8] [Reference Citation Analysis]
174 Tawar RG, Colpitts CC, Timm J, Fehm T, Roggendorf M, Meisel H, Meyer N, Habersetzer F, Cosset FL, Berg T, Zeisel MB, Baumert TF. Acute hepatitis C virus infection induces anti-host cell receptor antibodies with virus-neutralizing properties. Hepatology 2015;62:726-36. [PMID: 26010076 DOI: 10.1002/hep.27906] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
175 Boisvert M, Zhang W, Elrod EJ, Bernard NF, Villeneuve JP, Bruneau J, Marcotrigiano J, Shoukry NH, Grakoui A. Novel E2 Glycoprotein Tetramer Detects Hepatitis C Virus-Specific Memory B Cells. J Immunol 2016;197:4848-58. [PMID: 27849172 DOI: 10.4049/jimmunol.1600763] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
176 Dawood RM, Salum GM, Abdelhafez TH, El Shenawy R, Ibrahim NE, El Awady MK. Safety and tolerability of mice to repeated subcutaneous injections of a peptide mix as a potential vaccine against HCV infection. Hum Antibodies 2019;27:105-10. [PMID: 30594921 DOI: 10.3233/HAB-180354] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
177 Gremion C, Cerny A. Hepatitis C virus and the immune system: a concise review. Rev Med Virol. 2005;15:235-268. [PMID: 15782389 DOI: 10.1002/rmv.466] [Cited by in Crossref: 67] [Cited by in F6Publishing: 64] [Article Influence: 3.9] [Reference Citation Analysis]
178 Missiha SB, Ostrowski M, Heathcote EJ. Disease Progression in Chronic Hepatitis C: Modifiable and Nonmodifiable Factors. Gastroenterology 2008;134:1699-714. [DOI: 10.1053/j.gastro.2008.02.069] [Cited by in Crossref: 152] [Cited by in F6Publishing: 127] [Article Influence: 10.9] [Reference Citation Analysis]
179 Raghuraman S, Park H, Osburn WO, Winkelstein E, Edlin BR, Rehermann B. Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion. J Infect Dis 2012;205:763-71. [PMID: 22293431 DOI: 10.1093/infdis/jir835] [Cited by in Crossref: 111] [Cited by in F6Publishing: 111] [Article Influence: 11.1] [Reference Citation Analysis]
180 Tatsumi T, Takehara T, Miyagi T, Nakazuru S, Mita E, Kanto T, Hiramatsu N, Hayashi N. Hepatitis C virus-specific CD8+ T cell frequencies are associated with the responses of pegylated interferon-α and ribavirin combination therapy in patients with chronic hepatitis C virus infection. Hepatol Res. 2011;41:30-38. [PMID: 21040277 DOI: 10.1111/j.1872-034x.2010.00734.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
181 Wang S, Buchli R, Schiller J, Gao J, VanGundy RS, Hildebrand WH, Eckels DD. Natural epitope variants of the hepatitis C virus impair cytotoxic T lymphocyte activity. World J Gastroenterol 2010; 16(16): 1953-1969 [PMID: 20419832 DOI: 10.3748/wjg.v16.i16.1953] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
182 Dai JH, Iwatani Y, Ishida T, Terunuma H, Kasai H, Iwakula Y, Fujiwara H, Ito M. Glycyrrhizin enhances interleukin-12 production in peritoneal macrophages. Immunology 2001;103:235-43. [PMID: 11412311 DOI: 10.1046/j.1365-2567.2001.01224.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 2.3] [Reference Citation Analysis]
183 Shin EC, Seifert U, Kato T, Rice CM, Feinstone SM, Kloetzel PM, Rehermann B. Virus-induced type I IFN stimulates generation of immunoproteasomes at the site of infection. J Clin Invest. 2006;116:3006-3014. [PMID: 17039255 DOI: 10.1172/jci2983] [Cited by in Crossref: 28] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
184 Ray SC, Thomas DL. Hepatitis C. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Elsevier; 2010. pp. 2157-85. [DOI: 10.1016/b978-0-443-06839-3.00154-5] [Cited by in Crossref: 5] [Article Influence: 0.4] [Reference Citation Analysis]
185 Diepolder HM, Gruener NH, Gerlach JT, Jung MC, Wierenga EA, Pape GR. Different levels of T-cell receptor triggering induce distinct functions in hepatitis B and hepatitis C virus-specific human CD4(+) T-cell clones. J Virol 2001;75:7803-10. [PMID: 11483723 DOI: 10.1128/jvi.75.17.7803-7810.2001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
186 Mizukoshi E, Sidney J, Livingston B, Ghany M, Hoofnagle JH, Sette A, Rehermann B. Cellular immune responses to the hepatitis B virus polymerase. J Immunol. 2004;173:5863-5871. [PMID: 15494540 DOI: 10.4049/jimmunol.173.9.5863] [Cited by in Crossref: 66] [Cited by in F6Publishing: 61] [Article Influence: 3.7] [Reference Citation Analysis]
187 Semmo N, Klenerman P. CD4+ T cell responses in hepatitis C virus infection. World J Gastroenterol 2007; 13(36): 4831-4838 [PMID: 17828814 DOI: 10.3748/wjg.v13.i36.4831] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 35] [Article Influence: 2.5] [Reference Citation Analysis]
188 Grubor-Bauk B, Yu W, Wijesundara D, Gummow J, Garrod T, Brennan AJ, Voskoboinik I, Gowans EJ. Intradermal delivery of DNA encoding HCV NS3 and perforin elicits robust cell-mediated immunity in mice and pigs. Gene Ther 2016;23:26-37. [PMID: 26262584 DOI: 10.1038/gt.2015.86] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
189 Krishnadas DK, Li W, Kumar R, Tyrrell DL, Agrawal B. HCV-core and NS3 antigens play disparate role in inducing regulatory or effector T cells in vivo: Implications for viral persistence or clearance. Vaccine. 2010;28:2104-2114. [PMID: 20045096 DOI: 10.1016/j.vaccine.2009.12.037] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
190 Cox AL, Mosbruger T, Lauer GM, Pardoll D, Thomas DL, Ray SC. Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. Hepatology. 2005;42:104-112. [PMID: 15962289 DOI: 10.1002/hep.20749] [Cited by in Crossref: 154] [Cited by in F6Publishing: 167] [Article Influence: 9.1] [Reference Citation Analysis]
191 Swadling L, Capone S, Antrobus RD, Brown A, Richardson R, Newell EW, Halliday J, Kelly C, Bowen D, Fergusson J, Kurioka A, Ammendola V, Del Sorbo M, Grazioli F, Esposito ML, Siani L, Traboni C, Hill A, Colloca S, Davis M, Nicosia A, Cortese R, Folgori A, Klenerman P, Barnes E. A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Sci Transl Med. 2014;6:261ra153. [PMID: 25378645 DOI: 10.1126/scitranslmed.3009185] [Cited by in Crossref: 230] [Cited by in F6Publishing: 211] [Article Influence: 32.9] [Reference Citation Analysis]
192 Wiegand J, Potthoff A, Manns MP, Wedemeyer H. Acute hepatitis C infection: Can immunology teach us the right way to treat? Curr hepatitis rep 2004;3:148-56. [DOI: 10.1007/s11901-004-0025-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
193 Lefrère J, Girot R, Lefrère F, Guillaume N, Lerable J, Marrec NL, Bouchardeau F, Laperche S. Complete or partial seroreversion in immunocompetent individuals after self-limited HCV infection: consequences for transfusion: SEROREVERSION AF TER HCV INFECTION. Transfusion 2004;44:343-8. [DOI: 10.1111/j.1537-2995.2004.00656.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 1.9] [Reference Citation Analysis]
194 Firbas C, Jilma B, Tauber E, Buerger V, Jelovcan S, Lingnau K, Buschle M, Frisch J, Klade CS. Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: A randomized, placebo controlled trial for dose optimization in 128 healthy subjects. Vaccine 2006;24:4343-53. [DOI: 10.1016/j.vaccine.2006.03.009] [Cited by in Crossref: 101] [Cited by in F6Publishing: 89] [Article Influence: 6.3] [Reference Citation Analysis]
195 Woitas RP, Ahlenstiel G, Iwan A, Rockstroh JK, Brackmann HH, Kupfer B, Matz B, Offergeld R, Sauerbruch T, Spengler U. Frequency of the HIV-protective CC chemokine receptor 5-Delta32/Delta32 genotype is increased in hepatitis C. Gastroenterology. 2002;122:1721-1728. [PMID: 12055576 DOI: 10.1053/gast.2002.33660] [Cited by in Crossref: 80] [Cited by in F6Publishing: 80] [Article Influence: 4.0] [Reference Citation Analysis]
196 Abdel-Hakeem MS, Bédard N, Murphy D, Bruneau J, Shoukry NH. Signatures of protective memory immune responses during hepatitis C virus reinfection. Gastroenterology 2014;147:870-881.e8. [PMID: 25038432 DOI: 10.1053/j.gastro.2014.07.005] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 4.9] [Reference Citation Analysis]
197 Zhang X, Hu D, Zhu B, Wang C, He J, Wu J, Yu RB, Zhao WH. Tumor Necrosis Factor-α Promoter Gene Polymorphisms Are Not Associated with Hepatitis C Virus Infection in Chinese Hemodialysis Patients. Renal Failure 2011;33:593-9. [DOI: 10.3109/0886022x.2011.585265] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
198 Quiroga JA, Castillo I, Pardo M, Rodríguez-Iñigo E, Carreño V. Combined hepatitis C virus (HCV) antigen-antibody detection assay does not improve diagnosis for seronegative individuals with occult HCV infection. J Clin Microbiol 2006;44:4559-60. [PMID: 17021056 DOI: 10.1128/JCM.01440-06] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
199 Puig M, Major ME, Mihalik K, Feinstone SM. Immunization of chimpanzees with an envelope protein-based vaccine enhances specific humoral and cellular immune responses that delay hepatitis C virus infection. Vaccine. 2004;22:991-1000. [PMID: 15161076 DOI: 10.1016/j.vaccine.2003.09.010] [Cited by in Crossref: 60] [Cited by in F6Publishing: 57] [Article Influence: 3.3] [Reference Citation Analysis]
200 Mizukoshi E, Eisenbach C, Edlin BR, Newton KP, Raghuraman S, Weiler-Normann C, Tobler LH, Busch MP, Carrington M, McKeating JA. Hepatitis C virus (HCV)-specific immune responses of long-term injection drug users frequently exposed to HCV. J Infect Dis. 2008;198:203-212. [PMID: 18505381 DOI: 10.1086/589510] [Cited by in Crossref: 52] [Cited by in F6Publishing: 49] [Article Influence: 3.7] [Reference Citation Analysis]
201 Allain JP. Hepatitis C virus in blood donation. Lancet 2005;365:276-8. [PMID: 15664206 DOI: 10.1016/S0140-6736(05)17801-5] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
202 Nelson DR. THE IMMUNOPATHOGENESIS OF HEPATITIS C VIRUS INFECTION. Clinics in Liver Disease 2001;5:931-53. [DOI: 10.1016/s1089-3261(05)70202-6] [Cited by in Crossref: 33] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
203 Neumann-haefelin C, Mckiernan S, Ward S, Viazov S, Spangenberg HC, Killinger T, Baumert TF, Nazarova N, Sheridan I, Pybus O, von Weizsäcker F, Roggendorf M, Kelleher D, Klenerman P, Blum HE, Thimme R. Dominant influence of an HLA-B27 restricted CD8+ T cell response in mediating HCV clearance and evolution. Hepatology 2006;43:563-72. [DOI: 10.1002/hep.21049] [Cited by in Crossref: 151] [Cited by in F6Publishing: 149] [Article Influence: 9.4] [Reference Citation Analysis]
204 Bes M, Esteban JI, Casamitjana N, Piron M, Quer J, Cubero M, Puig L, Guardia J, Sauleda S. Hepatitis C virus (HCV)-specific T-cell responses among recombinant immunoblot assay-3-indeterminate blood donors: a confirmatory evidence of HCV exposure. Transfusion 2009;49:1296-305. [DOI: 10.1111/j.1537-2995.2009.02103.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
205 Chen RW, Piiparinen H, Seppänen M, Koskela P, Sarna S, Lappalainen M. Real-time PCR for detection and quantitation of hepatitis B virus DNA. J Med Virol. 2001;65:250-256. [PMID: 11536230 DOI: 10.1002/jmv.2027] [Cited by in Crossref: 70] [Cited by in F6Publishing: 69] [Article Influence: 3.3] [Reference Citation Analysis]
206 Werner JM, Abdalla A, Gara N, Ghany MG, Rehermann B. The hepatitis B vaccine protects re-exposed health care workers, but does not provide sterilizing immunity. Gastroenterology 2013;145:1026-34. [PMID: 23916846 DOI: 10.1053/j.gastro.2013.07.044] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
207 Grebely J, Thomas DL, Dore GJ. HCV reinfection studies and the door to vaccine development. Journal of Hepatology 2009;51:628-31. [DOI: 10.1016/j.jhep.2009.07.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
208 McCaughan GW, Zekry A. Pathogenesis of hepatitis C virus recurrence in the liver allograft. Liver Transpl 2002;8:S7-S13. [PMID: 12362292 DOI: 10.1053/jlts.2002.35856] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 2.3] [Reference Citation Analysis]
209 Wölk B, Gremion C, Ivashkina N, Engler OB, Grabscheid B, Bieck E, Blum HE, Cerny A, Moradpour D. Stable human lymphoblastoid cell lines constitutively expressing hepatitis C virus proteins. Journal of General Virology 2005;86:1737-46. [DOI: 10.1099/vir.0.80853-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
210 Wüest T, Both GW, Prince AM, Hofmann C, Löser P. Recombinant ovine atadenovirus induces a strong and sustained T cell response against the hepatitis C virus NS3 antigen in mice. Vaccine 2004;22:2717-21. [PMID: 15246602 DOI: 10.1016/j.vaccine.2004.01.048] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 1.7] [Reference Citation Analysis]
211 Schulze Zur Wiesch J, Ciuffreda D, Lewis-Ximenez L, Kasprowicz V, Nolan BE, Streeck H, Aneja J, Reyor LL, Allen TM, Lohse AW, McGovern B, Chung RT, Kwok WW, Kim AY, Lauer GM. Broadly directed virus-specific CD4+ T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human blood with viral persistence. J Exp Med 2012;209:61-75. [PMID: 22213804 DOI: 10.1084/jem.20100388] [Cited by in Crossref: 155] [Cited by in F6Publishing: 149] [Article Influence: 15.5] [Reference Citation Analysis]
212 Rao HY, Sun DG, Yang RF, Liu F, Wang J, Feng B, Wu N, Fang JL, Song GJ, Ma H. Outcome of hepatitis C virus infection in Chinese paid plasma donors: a 12-19-year cohort study. J Gastroenterol Hepatol. 2012;27:526-532. [PMID: 21871021 DOI: 10.1111/j.1440-1746.2011.06880.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
213 Schott E, Witt H, Hinrichsen H, Neumann K, Weich V, Bergk A, Halangk J, Müller T, Tinjala S, Puhl G. Gender-dependent association of CTLA4 polymorphisms with resolution of hepatitis C virus infection. J Hepatol. 2007;46:372-380. [PMID: 17150279 DOI: 10.1016/j.jhep.2006.09.011] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 2.1] [Reference Citation Analysis]
214 Bostan N, Mahmood T. An overview about hepatitis C: a devastating virus. Crit Rev Microbiol. 2010;36:91-133. [PMID: 20345213 DOI: 10.3109/10408410903357455] [Cited by in Crossref: 73] [Cited by in F6Publishing: 65] [Article Influence: 6.1] [Reference Citation Analysis]
215 Ratnoglik SL, Jiang DP, Aoki C, Sudarmono P, Shoji I, Deng L, Hotta H. Induction of cell-mediated immune responses in mice by DNA vaccines that express hepatitis C virus NS3 mutants lacking serine protease and NTPase/RNA helicase activities. PLoS One 2014;9:e98877. [PMID: 24901478 DOI: 10.1371/journal.pone.0098877] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
216 Seifert U, Liermann H, Racanelli V, Halenius A, Wiese M, Wedemeyer H, Ruppert T, Rispeter K, Henklein P, Sijts A. Hepatitis C virus mutation affects proteasomal epitope processing. J Clin Invest. 2004;114:250-259. [PMID: 15254592 DOI: 10.1172/jci200420985] [Cited by in Crossref: 109] [Cited by in F6Publishing: 1] [Article Influence: 6.1] [Reference Citation Analysis]
217 Spaan M, Janssen HL, Boonstra A. Immunology of hepatitis C virus infections. Best Pract Res Clin Gastroenterol. 2012;26:391-400. [PMID: 23199499 DOI: 10.1016/j.bpg.2012.09.005] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
218 Wang JH, Pianko MJ, Ke X, Herskovic A, Hershow R, Cotler SJ, Chen W, Chen ZW, Rong L. Characterization of antigenic variants of hepatitis C virus in immune evasion. Virol J 2011;8:377. [PMID: 21801418 DOI: 10.1186/1743-422X-8-377] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
219 Busch MP, Murthy KK, Kleinman SH, Hirschkorn DF, Herring BL, Delwart EL, Racanelli V, Yoon JC, Rehermann B, Alter HJ. Infectivity in chimpanzees (Pan troglodytes) of plasma collected before HCV RNA detectability by FDA-licensed assays: implications for transfusion safety and HCV infection outcomes. Blood 2012;119:6326-34. [PMID: 22498743 DOI: 10.1182/blood-2011-12-393637] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
220 Wertheimer A. Novel CD4+ and CD8+ T-cell determinants within the NS3 protein in subjects with spontaneously resolved HCV infection. Hepatology 2003;37:577-89. [DOI: 10.1053/jhep.2003.50115] [Cited by in Crossref: 97] [Cited by in F6Publishing: 92] [Article Influence: 5.1] [Reference Citation Analysis]
221 Wedemeyer H, Gagneten S, Davis A, Bartenschlager R, Feinstone S, Rehermann B. Oral immunization with HCV-NS3-transformed Salmonella: induction of HCV-specific CTL in a transgenic mouse model. Gastroenterology. 2001;121:1158-1166. [PMID: 11677208 DOI: 10.1053/gast.2001.29311] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 2.2] [Reference Citation Analysis]
222 Shoukry NH. Towards a Systems Immunology Approach to Understanding Correlates of Protective Immunity against HCV. Viruses 2021;13:1871. [PMID: 34578451 DOI: 10.3390/v13091871] [Reference Citation Analysis]
223 Wiegand J, Jäckel E, Cornberg M, Hinrichsen H, Dietrich M, Kroeger J, Fritsch WP, Kubitschke A, Aslan N, Tillmann HL, Manns MP, Wedemeyer H. Long-term follow-up after successful interferon therapy of acute hepatitis C. Hepatology 2004;40:98-107. [DOI: 10.1002/hep.20291] [Cited by in Crossref: 69] [Cited by in F6Publishing: 63] [Article Influence: 3.8] [Reference Citation Analysis]
224 Zeisel MB, Fafi-Kremer S, Fofana I, Barth H, Stoll-Keller F, Doffoël M, Baumert TF. Neutralizing antibodies in hepatitis C virus infection. World J Gastroenterol 2007; 13(36): 4824-4830 [PMID: 17828813 DOI: 10.3748/wjg.v13.i36.4824] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 30] [Article Influence: 2.2] [Reference Citation Analysis]
225 Wietzke-braun P, Maouzi AB, M??nhardt LB, Bickeb??ller H, Ramadori G, Mihm S. Interferon regulatory factor-1 promoter polymorphism and the outcome of hepatitis C virus infection: . European Journal of Gastroenterology & Hepatology 2006;18:991-7. [DOI: 10.1097/01.meg.0000224478.89545.76] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 1.3] [Reference Citation Analysis]
226 Fang CT, Tobler LH, Haesche C, Busch MP, Phelps B, Leparc G. Fluctuation of HCV viral load before seroconversion in a healthy volunteer blood donor. Transfusion 2003;43:541-4. [DOI: 10.1046/j.1537-2995.2003.00355.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
227 Nascimbeni M, Shin EC, Chiriboga L, Kleiner DE, Rehermann B. Peripheral CD4(+)CD8(+) T cells are differentiated effector memory cells with antiviral functions. Blood. 2004;104:478-486. [PMID: 15044252 DOI: 10.1182/blood-2003-12-4395] [Cited by in Crossref: 164] [Cited by in F6Publishing: 163] [Article Influence: 9.1] [Reference Citation Analysis]
228 Spengler U, Nischalke HD, Nattermann J, Strassburg CP. Between Scylla and Charybdis: The role of the human immune system in the pathogenesis of hepatitis C. World J Gastroenterol 2013; 19(44): 7852-7866 [PMID: 24307779 DOI: 10.3748/wjg.v19.i44.7852] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
229 Li D, Schwarz KB. Immunopathogenesis of Chronic Hepatitis C Virus Infection: . Journal of Pediatric Gastroenterology and Nutrition 2002;35:260-7. [DOI: 10.1097/00005176-200209000-00005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
230 Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol. 2013;10:553-562. [PMID: 23817321 DOI: 10.1038/nrgastro.2013.107] [Cited by in Crossref: 625] [Cited by in F6Publishing: 583] [Article Influence: 69.4] [Reference Citation Analysis]
231 Rigopoulou EI, Abbott WG, Haigh P, Naoumov NV. Blocking of interleukin-10 receptor--a novel approach to stimulate T-helper cell type 1 responses to hepatitis C virus. Clin Immunol. 2005;117:57-64. [PMID: 16006191 DOI: 10.1016/j.clim.2005.06.003] [Cited by in Crossref: 70] [Cited by in F6Publishing: 66] [Article Influence: 4.1] [Reference Citation Analysis]
232 Meunier JC, Russell RS, Goossens V, Priem S, Walter H, Depla E, Union A, Faulk KN, Bukh J, Emerson SU, Purcell RH. Isolation and characterization of broadly neutralizing human monoclonal antibodies to the e1 glycoprotein of hepatitis C virus. J Virol 2008;82:966-73. [PMID: 17977972 DOI: 10.1128/JVI.01872-07] [Cited by in Crossref: 116] [Cited by in F6Publishing: 85] [Article Influence: 7.7] [Reference Citation Analysis]
233 Pfafferott K, Deshpande P, McKinnon E, Merani S, Lucas A, Heckerman D, Mallal S, John M, Gaudieri S, Lucas M. Anti-hepatitis C virus T-cell immunity in the context of multiple exposures to the virus. PLoS One 2015;10:e0130420. [PMID: 26107956 DOI: 10.1371/journal.pone.0130420] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
234 Nellore A, Fishman JA. NK cells, innate immunity and hepatitis C infection after liver transplantation. Clin Infect Dis. 2011;52:369-377. [PMID: 21217184 DOI: 10.1093/cid/ciq156] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
235 Manns MP, Buti M, Gane E, Pawlotsky JM, Razavi H, Terrault N, Younossi Z. Hepatitis C virus infection. Nat Rev Dis Primers. 2017;3:17006. [PMID: 28252637 DOI: 10.1038/nrdp.2017.6] [Cited by in Crossref: 189] [Cited by in F6Publishing: 162] [Article Influence: 37.8] [Reference Citation Analysis]
236 Boesecke C, Wedemeyer H, Rockstroh JK. Diagnosis and treatment of acute hepatitis C virus infection. Infect Dis Clin North Am 2012;26:995-1010. [PMID: 23083829 DOI: 10.1016/j.idc.2012.08.011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
237 Lyons S, Kapoor A, Schneider BS, Wolfe ND, Culshaw G, Corcoran B, Durham AE, Burden F, McGorum BC, Simmonds P. Viraemic frequencies and seroprevalence of non-primate hepacivirus and equine pegiviruses in horses and other mammalian species. J Gen Virol. 2014;95:1701-1711. [PMID: 24814924 DOI: 10.1099/vir.0.065094-0] [Cited by in Crossref: 67] [Cited by in F6Publishing: 59] [Article Influence: 8.4] [Reference Citation Analysis]
238 Meyer MF, Lehmann M, Cornberg M, Wiegand J, Manns MP, Klade C, Wedemeyer H. Clearance of low levels of HCV viremia in the absence of a strong adaptive immune response. Virol J 2007;4:58. [PMID: 17562015 DOI: 10.1186/1743-422X-4-58] [Cited by in Crossref: 32] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
239 Komatsu T, Virdee S. ICBS and ECBS Chemical Biology Meeting 2015 - Let Them Come to Berlin! ACS Chem Biol 2016;11:1159-66. [PMID: 27198933 DOI: 10.1021/acschembio.6b00268] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
240 Benavides JA, Caillaud D, Scurlock BM, Maichak EJ, Edwards WH, Cross PC. Estimating Loss of Brucella Abortus Antibodies from Age-Specific Serological Data In Elk. Ecohealth 2017;14:234-43. [PMID: 28508154 DOI: 10.1007/s10393-017-1235-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
241 Yoneda S, Umemura T, Katsuyama Y, Kamijo A, Joshita S, Komatsu M, Ichijo T, Matsumoto A, Yoshizawa K, Ota M, Tanaka E; Nagano Interferon Treatment Research Group. Association of serum cytokine levels with treatment response to pegylated interferon and ribavirin therapy in genotype 1 chronic hepatitis C patients. J Infect Dis 2011;203:1087-95. [PMID: 21398397 DOI: 10.1093/infdis/jiq165] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 3.5] [Reference Citation Analysis]
242 Penna A, Missale G, Lamonaca V, Pilli M, Mori C, Zanelli P, Cavalli A, Elia G, Ferrari C. Intrahepatic and circulating HLA class II-restricted, hepatitis C virus-specific T cells: functional characterization in patients with chronic hepatitis C. Hepatology. 2002;35:1225-1236. [PMID: 11981773 DOI: 10.1053/jhep.2002.33153] [Cited by in Crossref: 57] [Cited by in F6Publishing: 53] [Article Influence: 2.9] [Reference Citation Analysis]
243 Meunier JC, Engle RE, Faulk K, Zhao M, Bartosch B, Alter H, Emerson SU, Cosset FL, Purcell RH, Bukh J. Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1. Proc Natl Acad Sci U S A. 2005;102:4560-4565. [PMID: 15767578 DOI: 10.1073/pnas.0501275102.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
244 Gallegos-Orozco JF, Arenas JI, Vargas HE, Kibler KV, Wilkinson JK, Nowicki M, Radkowski M, Nasseri J, Rakela J, Laskus T. Selection of different 5' untranslated region hepatitis C virus variants during post-transfusion and post-transplantation infection. J Viral Hepat 2006;13:489-98. [PMID: 16792543 DOI: 10.1111/j.1365-2893.2006.00724.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
245 Shi J, Li Y, Chang W, Zhang X, Wang FS. Current progress in host innate and adaptive immunity against hepatitis C virus infection. Hepatol Int 2017;11:374-83. [PMID: 28643186 DOI: 10.1007/s12072-017-9805-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
246 Thimme R, Neumann-Haefelin C, Boettler T, Blum HE. Adaptive immune responses to hepatitis C virus: from viral immunobiology to a vaccine. Biol Chem. 2008;389:457-467. [PMID: 18953713 DOI: 10.1515/BC.2008.061] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
247 Leroux-Roels G. Development of prophylactic and therapeutic vaccines against hepatitis C virus. Expert Rev Vaccines 2005;4:351-71. [PMID: 16026249 DOI: 10.1586/14760584.4.3.351] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
248 Rallón NI, Soriano V, Benito JM. [Adaptive cell immune response against the hepatitis C virus infection]. Med Clin (Barc) 2007;129:469-76. [PMID: 17953913 DOI: 10.1157/13111005] [Reference Citation Analysis]
249 Aebi-Popp K, Wandeler G, Salazar-Vizcaya L, Metzner K, Stöckle M, Cavassini M, Hoffmann M, Lüthi A, Suter F, Bernasconi E, Fehr J, Furrer H, Rauch A; the Swiss HIV Cohort Study. Rapid decline of anti-hepatitis C virus (HCV) antibodies following early treatment of incident HCV infections in HIV-infected men who have sex with men. HIV Med 2018;19:420-5. [PMID: 29573533 DOI: 10.1111/hiv.12602] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
250 Barth H. Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade. World J Hepatol 2015; 7(5): 725-737 [PMID: 25914773 DOI: 10.4254/wjh.v7.i5.725] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 5.4] [Reference Citation Analysis]
251 Samri A, Roque-afonso A, Beran O, Tateo M, Teicher E, Feray C, Sebagh M, Guettier C, Dussaix E, Vittecoq D, Samuel D, Autran B, Duclos-vallée J. Preservation of immune function and anti-hepatitis C virus (HCV) immune responses after liver transplantation in HIV–HCV coinfected patients (ANRS-HC08 “THEVIC” trial). Journal of Hepatology 2009;51:1000-9. [DOI: 10.1016/j.jhep.2009.06.031] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
252 Kamal SM, Rasenack JW, Bianchi L, Al Tawil A, El Sayed Khalifa K, Peter T, Mansour H, Ezzat W, Koziel M. Acute hepatitis C without and with schistosomiasis: correlation with hepatitis C-specific CD4(+) T-cell and cytokine response. Gastroenterology. 2001;121:646-656. [PMID: 11522749 DOI: 10.1053/gast.2001.27024] [Cited by in Crossref: 107] [Cited by in F6Publishing: 100] [Article Influence: 5.1] [Reference Citation Analysis]
253 Kamal SM, Fehr J, Roesler B, Peters T, Rasenack JW. Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C. Gastroenterology. 2002;123:1070-1083. [PMID: 12360469 DOI: 10.1053/gast.2002.36045] [Cited by in Crossref: 138] [Cited by in F6Publishing: 127] [Article Influence: 6.9] [Reference Citation Analysis]
254 Mu X, Zhang L, Chang S, Cui W, Zheng Z. Multiplex Microfluidic Paper-based Immunoassay for the Diagnosis of Hepatitis C Virus Infection. Anal Chem 2014;86:5338-44. [DOI: 10.1021/ac500247f] [Cited by in Crossref: 81] [Cited by in F6Publishing: 71] [Article Influence: 10.1] [Reference Citation Analysis]
255 Utsumi M, Takaki A, Umeda Y, Koike K, Napier SC, Watanabe N, Sadamori H, Shinoura S, Yoshida R, Nobuoka D, Yasunaka T, Nakayama E, Yamamoto K, Fujiwara T, Yagi T. Frequency of regulatory T-cell and hepatitis C viral antigen-specific immune response in recurrent hepatitis C after liver transplantation. Transpl Immunol 2014;31:33-41. [PMID: 24907425 DOI: 10.1016/j.trim.2014.05.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
256 Kim AY, Chung RT. Coinfection with HIV-1 and HCV-a one-two punch. Gastroenterology. 2009;137:795-814. [PMID: 19549523 DOI: 10.1053/j.gastro.2009.06.040] [Cited by in Crossref: 125] [Cited by in F6Publishing: 112] [Article Influence: 9.6] [Reference Citation Analysis]
257 Folgori A, Spada E, Pezzanera M, Ruggeri L, Mele A, Garbuglia AR, Perrone MP, Del Porto P, Piccolella E, Cortese R. Early impairment of hepatitis C virus specific T cell proliferation during acute infection leads to failure of viral clearance. Gut. 2006;55:1012-1019. [PMID: 16484505 DOI: 10.1136/gut.2005.080077] [Cited by in Crossref: 60] [Cited by in F6Publishing: 60] [Article Influence: 3.8] [Reference Citation Analysis]
258 Shata MT, Tricoche N, Perkus M, Tom D, Brotman B, Mccormack P, Pfahler W, Lee D, Tobler LH, Busch M, Prince AM. Exposure to low infective doses of HCV induces cellular immune responses without consistently detectable viremia or seroconversion in chimpanzees. Virology 2003;314:601-16. [DOI: 10.1016/s0042-6822(03)00461-6] [Cited by in Crossref: 53] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
259 Szabo G, Dolganiuc A. HCV Immunopathogenesis: Virus-Induced Strategies against Host Immunity. Clinics in Liver Disease 2006;10:753-71. [DOI: 10.1016/j.cld.2006.08.028] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
260 Gruener NH, Lechner F, Jung MC, Diepolder H, Gerlach T, Lauer G, Walker B, Sullivan J, Phillips R, Pape GR. Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus. J Virol. 2001;75:5550-5558. [PMID: 11356962 DOI: 10.1128/jvi.75.12.5550-5558] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
261 Hoofnagle JH. Course and outcome of hepatitis C. Hepatology. 2002;36:S21-S29. [PMID: 12407573 DOI: 10.1002/hep.1840360704] [Cited by in Crossref: 382] [Cited by in F6Publishing: 233] [Article Influence: 19.1] [Reference Citation Analysis]
262 Manfras BJ, Reuter S, Wendland T, Kern P. Increased activation and oligoclonality of peripheral CD8(+) T cells in the chronic human helminth infection alveolar echinococcosis. Infect Immun 2002;70:1168-74. [PMID: 11854197 DOI: 10.1128/IAI.70.3.1168-1174.2002] [Cited by in Crossref: 23] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
263 Bharadwaj M, Thammanichanond D, Aitken CK, Moneer S, Drummer HE, Tracy S, Holdsworth R, Bowden S, Jackson D, Hellard M, Torresi J, Mccluskey J. T CD8 response in diverse outcomes of recurrent exposure to hepatitis C virus. Immunol Cell Biol 2009;87:464-72. [DOI: 10.1038/icb.2009.24] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
264 Porter DL, June CH. T-cell reconstitution and expansion after hematopoietic stem cell transplantation: 'T' it up! Bone Marrow Transplant 2005;35:935-42. [PMID: 15806121 DOI: 10.1038/sj.bmt.1704953] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 2.1] [Reference Citation Analysis]
265 Wieland SF, Chisari FV. Stealth and cunning: hepatitis B and hepatitis C viruses. J Virol. 2005;79:9369-9380. [PMID: 16014900 DOI: 10.1128/jvi.79.15.9369-9380.2005] [Cited by in Crossref: 303] [Cited by in F6Publishing: 155] [Article Influence: 17.8] [Reference Citation Analysis]
266 Chang KM. Immunopathogenesis of hepatitis C virus infection. Clin Liver Dis. 2003;7:89-105. [PMID: 12691460 DOI: 10.1016/S1089-3261(02)00068-5] [Cited by in Crossref: 65] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
267 Piazzolla G, Nuzzaci M, Tortorella C, Panella E, Natilla A, Boscia D, De Stradis A, Piazzolla P, Antonaci S. Immunogenic Properties of a Chimeric Plant Virus Expressing a Hepatitis C Virus (HCV)-Derived Epitope: New Prospects for an HCV Vaccine. J Clin Immunol 2005;25:142-52. [DOI: 10.1007/s10875-005-2820-4] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
268 Chen AY, Hoare M, Shankar AN, Allison M, Alexander GJ, Michalak TI. Persistence of Hepatitis C Virus Traces after Spontaneous Resolution of Hepatitis C. PLoS One 2015;10:e0140312. [PMID: 26473969 DOI: 10.1371/journal.pone.0140312] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
269 Fitzmaurice K, Petrovic D, Ramamurthy N, Simmons R, Merani S, Gaudieri S, Sims S, Dempsey E, Freitas E, Lea S. Molecular footprints reveal the impact of the protective HLA-A*03 allele in hepatitis C virus infection. Gut. 2011;60:1563-1571. [PMID: 21551190 DOI: 10.1136/gut.2010.228403] [Cited by in Crossref: 54] [Cited by in F6Publishing: 57] [Article Influence: 4.9] [Reference Citation Analysis]
270 Arrojo IP, Pareja MO, Orta MDR, Luque FN, Lamas MCH, Gordo HS, Mancha IV. Detection of a healthy carrier of HCV with no evidence of antibodies for over four years: HEALTHY DONOR WITH HCV BUT NO ANTIBODIES. Transfusion 2003;43:953-7. [DOI: 10.1046/j.1537-2995.2003.00445.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
271 Tarantino G, Marco VD, Petta S, Almasio PL, Barbaria F, Licata A, Bosco GL, Tripodo C, Stefano RD, Craxì A. Serum BLyS/BAFF predicts the outcome of acute hepatitis C virus infection. Journal of Viral Hepatitis 2009;16:397-405. [DOI: 10.1111/j.1365-2893.2009.01093.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
272 Morishima C, Musey L, Elizaga M, Gaba K, Allison M, Carithers RL, Gretch DR, McElrath MJ. Hepatitis C virus-specific cytolytic T cell responses after antiviral therapy. Clin Immunol 2003;108:211-20. [PMID: 14499244 DOI: 10.1016/s1521-6616(03)00142-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
273 Racanelli V, Rehermann B. Hepatitis C virus infection: when silence is deception. Trends Immunol. 2003;24:456-464. [PMID: 12909460 DOI: 10.1016/s1471-4906(03)00178-9] [Cited by in Crossref: 77] [Cited by in F6Publishing: 28] [Article Influence: 4.1] [Reference Citation Analysis]
274 Kennedy PT, Urbani S, Moses RA, Amadei B, Fisicaro P, Lloyd J, Maini MK, Dusheiko G, Ferrari C, Bertoletti A. The influence of T cell cross-reactivity on HCV-peptide specific human T cell response. Hepatology. 2006;43:602-611. [PMID: 16496333 DOI: 10.1002/hep.21081] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 1.6] [Reference Citation Analysis]
275 Gerlach JT, Diepolder HM, Zachoval R, Gruener NH, Jung MC, Ulsenheimer A, Schraut WW, Schirren CA, Waechtler M, Backmund M. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology. 2003;125:80-88. [PMID: 12851873 DOI: 10.1016/s0016-5085(03)00668-1] [Cited by in Crossref: 343] [Cited by in F6Publishing: 122] [Article Influence: 18.1] [Reference Citation Analysis]
276 Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, Wieland SF, Uprichard SL, Wakita T, Chisari FV. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A. 2005;102:9294-9299. [PMID: 15939869 DOI: 10.1073/pnas.0503596102.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
277 von Hahn T, Yoon JC, Alter H, Rice CM, Rehermann B, Balfe P, Mckeating JA. Hepatitis C Virus Continuously Escapes From Neutralizing Antibody and T-Cell Responses During Chronic Infection In Vivo. Gastroenterology 2007;132:667-78. [DOI: 10.1053/j.gastro.2006.12.008] [Cited by in Crossref: 297] [Cited by in F6Publishing: 275] [Article Influence: 19.8] [Reference Citation Analysis]
278 Yu H, Huang H, Xiang J, Babiuk LA, van Drunen Littel-van den Hurk S. Dendritic cells pulsed with hepatitis C virus NS3 protein induce immune responses and protection from infection with recombinant vaccinia virus expressing NS3. J Gen Virol 2006;87:1-10. [PMID: 16361412 DOI: 10.1099/vir.0.81423-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
279 Shin EC, Seifert U, Kato T, Rice CM, Feinstone SM, Kloetzel PM, Rehermann B. Virus-induced type I IFN stimulates generation of immunoproteasomes at the site of infection. J Clin Invest. 2006;116:3006-3014. [PMID: 17039255 DOI: 10.1172/jci29832] [Cited by in Crossref: 110] [Cited by in F6Publishing: 70] [Article Influence: 6.9] [Reference Citation Analysis]
280 Koziel MJ. Cellular immune responses against hepatitis C virus. Clin Infect Dis. 2005;41 Suppl 1:S25-S31. [PMID: 16265610 DOI: 10.1086/429492] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 2.9] [Reference Citation Analysis]
281 Capa L, Soriano V, García-Samaniego J, Nuñez M, Romero M, Cascajero A, Muñoz F, González-Lahoz J, Benito JM. Influence of HCV genotype and co-infection with human immunodeficiency virus on CD4(+) and CD8(+) T-cell responses to hepatitis C virus. J Med Virol 2007;79:503-10. [PMID: 17385690 DOI: 10.1002/jmv.20856] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
282 Zeisel MB, Cosset FL, Baumert TF. Host neutralizing responses and pathogenesis of hepatitis C virus infection. Hepatology. 2008;48:299-307. [PMID: 18508291 DOI: 10.1002/hep.22307] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 2.7] [Reference Citation Analysis]
283 Hashem M, Jhaveri R, Saleh DA, Sharaf SA, El-Mougy F, Abdelsalam L, Shardell MD, El-Ghazaly H, El-Kamary SS. Spontaneous Viral Load Decline and Subsequent Clearance of Chronic Hepatitis C Virus in Postpartum Women Correlates With Favorable Interleukin-28B Gene Allele. Clin Infect Dis 2017;65:999-1005. [PMID: 28903504 DOI: 10.1093/cid/cix445] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
284 Siu L, Foont J, Wands JR. Hepatitis C virus and alcohol. Semin Liver Dis 2009;29:188-99. [PMID: 19387918 DOI: 10.1055/s-0029-1214374] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 3.9] [Reference Citation Analysis]
285 Martin P, Parroche P, Chatel L, Barretto C, Beck A, Trépo C, Bain C, Lone Y, Inchauspé G, Fournillier A. Genetic immunization and comprehensive screening approaches in HLA-A2 transgenic mice lead to the identification of three novel epitopes in hepatitis C virus NS3 antigen: Identification of Novel Class I Epitopes of HCV. J Med Virol 2004;74:397-405. [DOI: 10.1002/jmv.20189] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
286 Choi YS, Lee JE, Nam SJ, Park JT, Kim HS, Choi KH, Kim BS, Shin EC. Two distinct functional patterns of hepatitis C Virus (HCV)-specific T cell responses in seronegative, aviremic patients. PLoS One. 2013;8:e62319. [PMID: 23638039 DOI: 10.1371/journal.pone.0062319] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
287 Lauer GM, Barnes E, Lucas M, Timm J, Ouchi K, Kim AY, Day CL, Robbins GK, Casson DR, Reiser M. High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology. 2004;127:924-936. [PMID: 15362047 DOI: 10.1053/j.gastro.2004.06.015] [Cited by in Crossref: 221] [Cited by in F6Publishing: 221] [Article Influence: 12.3] [Reference Citation Analysis]
288 Mizukoshi E, Nascimbeni M, Blaustein JB, Mihalik K, Rice CM, Liang TJ, Feinstone SM, Rehermann B. Molecular and immunological significance of chimpanzee major histocompatibility complex haplotypes for hepatitis C virus immune response and vaccination studies. J Virol. 2002;76:6093-6103. [PMID: 12021342 DOI: 10.1128/JVI.76.12.6093-6103.2002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
289 Hara K, Rivera MM, Koh C, Demino M, Page S, Nagabhyru PR, Rehermann B, Liang TJ, Hoofnagle JH, Heller T. Sequence analysis of hepatitis C virus from patients with relapse after a sustained virological response: relapse or reinfection? J Infect Dis. 2014;209:38-45. [PMID: 24127561 DOI: 10.1093/infdis/jit541] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
290 Ciuffreda D, Kim AY. Update on hepatitis C virus-specific immunity. Curr Opin HIV AIDS 2011;6:559-65. [PMID: 22001897 DOI: 10.1097/COH.0b013e32834b879e] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
291 Pestka JM, Zeisel MB, Bläser E, Schürmann P, Bartosch B, Cosset FL, Patel AH, Meisel H, Baumert J, Viazov S, Rispeter K, Blum HE, Roggendorf M, Baumert TF. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci U S A 2007;104:6025-30. [PMID: 17392433 DOI: 10.1073/pnas.0607026104] [Cited by in Crossref: 370] [Cited by in F6Publishing: 374] [Article Influence: 24.7] [Reference Citation Analysis]
292 Smith S, Honegger JR, Walker C. T-Cell Immunity against the Hepatitis C Virus: A Persistent Research Priority in an Era of Highly Effective Therapy. Cold Spring Harb Perspect Med 2021;11:a036954. [PMID: 32205413 DOI: 10.1101/cshperspect.a036954] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
293 Muhanna N, Doron S, Wald O, Horani A, Eid A, Pappo O, Friedman SL, Safadi R. Activation of hepatic stellate cells after phagocytosis of lymphocytes: A novel pathway of fibrogenesis. Hepatology. 2008;48:963-977. [PMID: 18726940 DOI: 10.1002/hep.22413] [Cited by in Crossref: 98] [Cited by in F6Publishing: 92] [Article Influence: 7.0] [Reference Citation Analysis]
294 Rahman F, Heller T, Sobao Y, Mizukoshi E, Nascimbeni M, Alter H, Herrine S, Hoofnagle J, Liang TJ, Rehermann B. Effects of antiviral therapy on the cellular immune response in acute hepatitis C. Hepatology. 2004;40:87-97. [PMID: 15239090 DOI: 10.1002/hep.20253] [Cited by in Crossref: 95] [Cited by in F6Publishing: 101] [Article Influence: 5.3] [Reference Citation Analysis]
295 Caraballo Cortés K, Osuch S, Perlejewski K, Pawełczyk A, Kaźmierczak J, Janiak M, Jabłońska J, Nazzal K, Stelmaszczyk-Emmel A, Berak H, Bukowska-Ośko I, Paciorek M, Laskus T, Radkowski M. Expression of programmed cell death protein 1 and T-cell immunoglobulin- and mucin-domain-containing molecule-3 on peripheral blood CD4+CD8+ double positive T cells in patients with chronic hepatitis C virus infection and in subjects who spontaneously cleared the virus. J Viral Hepat 2019;26:942-50. [PMID: 30972915 DOI: 10.1111/jvh.13108] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
296 Li T, Zhu S, Shuai L, Xu Y, Yin S, Bian Y, Wang Y, Zuo B, Wang W, Zhao S, Zhang L, Zhang J, Gao GF, Allain JP, Li C. Infection of common marmosets with hepatitis C virus/GB virus-B chimeras. Hepatology 2014;59:789-802. [PMID: 24123143 DOI: 10.1002/hep.26750] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
297 Bassat HE, Ali LA, Alm El-din RA, Hasby E, Shahbah A. Serum level of interleukin-10 with its gene polymorphism can be predictors of response to treatment in Egyptian patients with chronic hepatitis C virus. Egyptian Journal of Medical Human Genetics 2013;14:227-33. [DOI: 10.1016/j.ejmhg.2013.03.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
298 Palmateer NE, Taylor A, Goldberg DJ, Munro A, Aitken C, Shepherd SJ, McAllister G, Gunson R, Hutchinson SJ. Rapid decline in HCV incidence among people who inject drugs associated with national scale-up in coverage of a combination of harm reduction interventions. PLoS One 2014;9:e104515. [PMID: 25110927 DOI: 10.1371/journal.pone.0104515] [Cited by in Crossref: 68] [Cited by in F6Publishing: 60] [Article Influence: 8.5] [Reference Citation Analysis]
299 Grebely J, Page K, Sacks-Davis R, van der Loeff MS, Rice TM, Bruneau J, Morris MD, Hajarizadeh B, Amin J, Cox AL, Kim AY, McGovern BH, Schinkel J, George J, Shoukry NH, Lauer GM, Maher L, Lloyd AR, Hellard M, Dore GJ, Prins M; InC3 Study Group. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology. 2014;59:109-120. [PMID: 23908124 DOI: 10.1002/hep.26639] [Cited by in Crossref: 236] [Cited by in F6Publishing: 220] [Article Influence: 26.2] [Reference Citation Analysis]
300 Elrefaei M, El-sheikh N, Kamal K, Cao H. Analysis of T cell responses against hepatitis C virus genotype 4 in Egypt. J Hepatol. 2004;40:313-318. [PMID: 14739104 DOI: 10.1016/j.jhep.2003.10.007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 0.9] [Reference Citation Analysis]
301 Sarobe P, Lasarte JJ, García N, Civeira MP, Borrás-Cuesta F, Prieto J. Characterization of T-cell responses against immunodominant epitopes from hepatitis C virus E2 and NS4a proteins. J Viral Hepat. 2006;13:47-55. [PMID: 16364082 DOI: 10.1111/j.1365-2893.2005.00653.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
302 Godkin AJ, Thomas HC, Openshaw PJ. Evolution of Epitope-Specific Memory CD4 + T Cells After Clearance of Hepatitis C Virus. J Immunol 2002;169:2210-4. [DOI: 10.4049/jimmunol.169.4.2210] [Cited by in Crossref: 79] [Cited by in F6Publishing: 83] [Article Influence: 4.0] [Reference Citation Analysis]
303 Flynn JK, Sacks-Davis R, Higgs P, Aitken C, Moneer S, Suppiah V, Tracy L, Ffrench R, Bowden S, Drummer H, George J, Bharadwaj M, Hellard M. Detection of HCV-Specific IFN-γ Responses in HCV Antibody and HCV RNA Negative Injecting Drug Users. Hepat Mon 2014;14:e14678. [PMID: 24497881 DOI: 10.5812/hepatmon.14678] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
304 Forns X. [Molecular biology of hepatitis C virus: implications for the development of new therapies and prophylactic vaccine]. Med Clin (Barc) 2001;116:191-7. [PMID: 11222177 DOI: 10.1016/s0025-7753(01)71766-6] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
305 Plauzolles A, Lucas M, Gaudieri S. Influence of host resistance on viral adaptation: hepatitis C virus as a case study. Infect Drug Resist 2015;8:63-74. [PMID: 25897250 DOI: 10.2147/IDR.S49891] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
306 Miyashita K, Hongo Y, Nakashima A, Kato S, Kusano H, Morizono S, Higashi N. Fatal Hepatitis C after Chemotherapy in a Patient with Malignant Lymphoma: Possible Reactivation of Seronegative Occult Hepatitis C Virus Infection Due to Chemotherapy. Intern Med 2021;60:1533-9. [PMID: 33191319 DOI: 10.2169/internalmedicine.4768-20] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
307 Lee LM, Henderson DK. Emerging viral infections: . Current Opinion in Infectious Diseases 2001;14:467-80. [DOI: 10.1097/00001432-200108000-00012] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
308 Krajden M, Ziermann R, Khan A, Mak A, Leung K, Hendricks D, Comanor L. Qualitative detection of hepatitis C virus RNA: comparison of analytical sensitivity, clinical performance, and workflow of the Cobas Amplicor HCV test version 2.0 and the HCV RNA transcription-mediated amplification qualitative assay. J Clin Microbiol 2002;40:2903-7. [PMID: 12149349 DOI: 10.1128/JCM.40.8.2903-2907.2002] [Cited by in Crossref: 38] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
309 Schirren CA, Zachoval R, Gerlach JT, Ulsenheimer A, Gruener NH, Diepolder HM, Baretton G, Schraut W, Rau H, Nitschko H, Pape GR, Jung M. Antiviral treatment of recurrent hepatitis C virus (HCV) infection after liver transplantation: association of a strong, multispecific, and long-lasting CD4+ T cell response with HCV-elimination. Journal of Hepatology 2003;39:397-404. [DOI: 10.1016/s0168-8278(03)00266-6] [Cited by in Crossref: 24] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
310 He X, Greenberg HB. CD8 + T-Cell Response Against Hepatitis C Virus. Viral Immunology 2002;15:121-31. [DOI: 10.1089/088282402317340279] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
311 Holz L, Rehermann B. T cell responses in hepatitis C virus infection: historical overview and goals for future research. Antiviral Res 2015;114:96-105. [PMID: 25433310 DOI: 10.1016/j.antiviral.2014.11.009] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 4.3] [Reference Citation Analysis]
312 Meyer K, Basu A, Przysiecki CT, Lagging LM, Di Bisceglie AM, Conley AJ, Ray R. Complement-mediated enhancement of antibody function for neutralization of pseudotype virus containing hepatitis C virus E2 chimeric glycoprotein. J Virol. 2002;76:2150-2158. [PMID: 11836392 DOI: 10.1128/jvi.76.5.2150-2158.2002] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 1.8] [Reference Citation Analysis]
313 Ruff CT, Ray SC, Kwon P, Zinn R, Pendleton A, Hutton N, Ashworth R, Gange S, Quinn TC, Siliciano RF, Persaud D. Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure. J Virol 2002;76:9481-92. [PMID: 12186930 DOI: 10.1128/jvi.76.18.9481-9492.2002] [Cited by in Crossref: 94] [Cited by in F6Publishing: 52] [Article Influence: 4.7] [Reference Citation Analysis]
314 Castillo I, Bartolomé J, Quiroga JA, Barril G, Carreño V. Long-term virological follow up of patients with occult hepatitis C virus infection. Liver Int 2011;31:1519-24. [PMID: 22093326 DOI: 10.1111/j.1478-3231.2011.02613.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
315 Khatun M, Ray R, Ray RB. Hepatitis C virus associated hepatocellular carcinoma. Adv Cancer Res 2021;149:103-42. [PMID: 33579422 DOI: 10.1016/bs.acr.2020.10.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
316 Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 2005;436:946-52. [PMID: 16107834 DOI: 10.1038/nature04079] [Cited by in Crossref: 557] [Cited by in F6Publishing: 523] [Article Influence: 32.8] [Reference Citation Analysis]
317 Zhang X, Dou J, Germann MW. Characterization of the cellular immune response in hepatitis C virus infection. Med Res Rev 2009;29:843-66. [PMID: 19378287 DOI: 10.1002/med.20157] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
318 Mina MM, Luciani F, Cameron B, Bull RA, Beard MR, Booth D, Lloyd AR. Resistance to hepatitis C virus: potential genetic and immunological determinants. Lancet Infect Dis. 2015;15:451-460. [PMID: 25703062 DOI: 10.1016/s1473-3099(14)70965-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
319 Vella LA, Herati RS, Wherry EJ. CD4+ T Cell Differentiation in Chronic Viral Infections: The Tfh Perspective. Trends Mol Med 2017;23:1072-87. [PMID: 29137933 DOI: 10.1016/j.molmed.2017.10.001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
320 Shin EC, Capone S, Cortese R, Colloca S, Nicosia A, Folgori A, Rehermann B. The kinetics of hepatitis C virus-specific CD8 T-cell responses in the blood mirror those in the liver in acute hepatitis C virus infection. J Virol. 2008;82:9782-9788. [PMID: 18667501 DOI: 10.1128/jvi.00475-08] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
321 Mccaughan GW, Zekry A. Mechanisms of HCV reinfection and allograft damage after liver transplantation. Journal of Hepatology 2004;40:368-74. [DOI: 10.1016/j.jhep.2004.01.014] [Cited by in Crossref: 79] [Cited by in F6Publishing: 64] [Article Influence: 4.4] [Reference Citation Analysis]
322 Harfouch S, Guiguet M, Valantin M, Samri A, Ouazene Z, Slama L, Dominguez S, Simon A, Theodorou I, Thibault V, Autran B. Lack of TGF-β production by hepatitis C virus-specific T cells during HCV acute phase is associated with HCV clearance in HIV coinfection. Journal of Hepatology 2012;56:1259-68. [DOI: 10.1016/j.jhep.2012.01.021] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
323 Lancaster T, Sanders E, Christie JML, Brooks C, Green S, Rosenberg WMC. Quantitative and functional differences in CD8+ lymphocyte responses in resolved acute and chronic hepatitis C virus infection. J Viral Hepat 2002;9:18-28. [DOI: 10.1046/j.1365-2893.2002.00330.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
324 Klenerman P, Kim A. HCV-HIV coinfection: simple messages from a complex disease. PLoS Med 2007;4:e240. [PMID: 17927445 DOI: 10.1371/journal.pmed.0040240] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
325 Simmonds P. Genetic diversity and evolution of hepatitis C virus--15 years on. J Gen Virol 2004;85:3173-88. [PMID: 15483230 DOI: 10.1099/vir.0.80401-0] [Cited by in Crossref: 590] [Cited by in F6Publishing: 582] [Article Influence: 32.8] [Reference Citation Analysis]
326 Nikolopoulou GB, Nowicki MJ, Du W, Homans J, Stek A, Kramer F, Kovacs A. HCV viremia is associated with drug use in young HIV-1 and HCV coinfected pregnant and non-pregnant women. Addiction 2005;100:626-35. [PMID: 15847620 DOI: 10.1111/j.1360-0443.2005.01054.x] [Reference Citation Analysis]
327 Ward S, Lauer G, Isba R, Walker B, Klenerman P. Cellular immune responses against hepatitis C virus: the evidence base 2002. Clin Exp Immunol. 2002;128:195-203. [PMID: 11985510 DOI: 10.1046/j.1365-2249.2002.01840.x] [Cited by in Crossref: 110] [Cited by in F6Publishing: 106] [Article Influence: 5.5] [Reference Citation Analysis]
328 Chang K. Regulatory T cells in hepatitis C virus infection. Hepatology Research 2007;37:S327-30. [DOI: 10.1111/j.1872-034x.2007.00220.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
329 Moriishi K, Matsuura Y. Mechanisms of hepatitis C virus infection. Antivir Chem Chemother 2003;14:285-97. [PMID: 14968935 DOI: 10.1177/095632020301400601] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
330 Vaghefi P, Roque-afonso A, Dussaix E. Séroréversion rapide après résolution spontanée de l'hépatite C aiguë chez un patient VIH positif. Pathologie Biologie 2006;54:347-8. [DOI: 10.1016/j.patbio.2006.01.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
331 Spada E, Mele A, Berton A, Ruggeri L, Ferrigno L, Garbuglia AR, Perrone MP, Girelli G, Del Porto P, Piccolella E, Mondelli MU, Amoroso P, Cortese R, Nicosia A, Vitelli A, Folgori A. Multispecific T cell response and negative HCV RNA tests during acute HCV infection are early prognostic factors of spontaneous clearance. Gut. 2004;53:1673-1681. [PMID: 15479691 DOI: 10.1136/gut.2003.037788] [Cited by in Crossref: 72] [Cited by in F6Publishing: 73] [Article Influence: 4.0] [Reference Citation Analysis]
332 García-retortillo M, Forns X. Variabilidad genómica e historia natural de la infección por el virus de la hepatitis C. Gastroenterología y Hepatología 2002;25:514-20. [DOI: 10.1016/s0210-5705(02)70303-8] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
333 Wang JH, Zheng X, Ke X, Dorak MT, Shen J, Boodram B, O'Gorman M, Beaman K, Cotler SJ, Hershow R, Rong L. Ethnic and geographical differences in HLA associations with the outcome of hepatitis C virus infection. Virol J 2009;6:46. [PMID: 19409091 DOI: 10.1186/1743-422X-6-46] [Cited by in Crossref: 25] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
334 Spengler U, Nattermann J. Immunopathogenesis in hepatitis C virus cirrhosis. Clin Sci (Lond) 2007;112:141-55. [PMID: 17199558 DOI: 10.1042/CS20060171] [Cited by in Crossref: 59] [Cited by in F6Publishing: 30] [Article Influence: 3.9] [Reference Citation Analysis]
335 Geraminejad P, Walling HW, Voigt MD, Stone MS. Severe erythema multiforme responding to interferon alfa. Journal of the American Academy of Dermatology 2006;54:S18-21. [DOI: 10.1016/j.jaad.2005.04.042] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
336 Takao Y, Yamada A, Yutani S, Takedatsu H, Ono T, Etoh K, Wang Y, Suzuki S, Ide T, Shimotohno K, Sata M, Itoh K. Identification of new immunogenic peptides in conserved regions of hepatitis C virus (HCV) 1b with the potentiality to generate cytotoxic T lymphocytes in HCV1b + HLA-A24 + patients. Hepatology Research 2007;37:186-95. [DOI: 10.1111/j.1872-034x.2007.00018.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
337 Forns X, Bukh J, Purcell RH. The challenge of developing a vaccine against hepatitis C virus. J Hepatol. 2002;37:684-695. [PMID: 12399239 DOI: 10.1016/s0168-8278(02)00308-2] [Cited by in Crossref: 57] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
338 Kim AY, Lauer GM, Ouchi K, Addo MM, Lucas M, Wiesch JSZ, Timm J, Boczanowski M, Duncan JE, Wurcel AG, Casson D, Chung RT, Draenert R, Klenerman P, Walker BD. The magnitude and breadth of hepatitis C virus–specific CD8+ T cells depend on absolute CD4+ T-cell count in individuals coinfected with HIV-1. Blood 2005;105:1170-8. [DOI: 10.1182/blood-2004-06-2336] [Cited by in Crossref: 77] [Cited by in F6Publishing: 77] [Article Influence: 4.5] [Reference Citation Analysis]
339 Gruener NH, Lechner F, Jung MC, Diepolder H, Gerlach T, Lauer G, Walker B, Sullivan J, Phillips R, Pape GR, Klenerman P. Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus. J Virol 2001;75:5550-8. [PMID: 11356962 DOI: 10.1128/JVI.75.12.5550-5558.2001] [Cited by in Crossref: 379] [Cited by in F6Publishing: 185] [Article Influence: 18.0] [Reference Citation Analysis]
340 Meier V, Ramadori G. Hepatitis C virus virology and new treatment targets. Expert Rev Anti Infect Ther 2009;7:329-50. [PMID: 19344246 DOI: 10.1586/eri.09.12] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
341 Rehermann B, Bertoletti A. Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections. Hepatology 2015;61:712-21. [PMID: 25048716 DOI: 10.1002/hep.27323] [Cited by in Crossref: 102] [Cited by in F6Publishing: 103] [Article Influence: 14.6] [Reference Citation Analysis]
342 Neveu B, Debeaupuis E, Echasserieau K, le Moullac-Vaidye B, Gassin M, Jegou L, Decalf J, Albert M, Ferry N, Gournay J, Houssaint E, Bonneville M, Saulquin X. Selection of high-avidity CD8 T cells correlates with control of hepatitis C virus infection. Hepatology 2008;48:713-22. [PMID: 18712791 DOI: 10.1002/hep.22379] [Cited by in Crossref: 50] [Cited by in F6Publishing: 50] [Article Influence: 3.6] [Reference Citation Analysis]
343 Abdel-Hakeem MS, Shoukry NH. Protective immunity against hepatitis C: many shades of gray. Front Immunol. 2014;5:274. [PMID: 24982656 DOI: 10.3389/fimmu.2014.00274] [Cited by in Crossref: 51] [Cited by in F6Publishing: 60] [Article Influence: 6.4] [Reference Citation Analysis]
344 Doyle JS, Hellard ME, Thompson AJ. The role of viral and host genetics in natural history and treatment of chronic HCV infection. Best Pract Res Clin Gastroenterol. 2012;26:413-427. [PMID: 23199501 DOI: 10.1016/j.bpg.2012.09.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
345 Lucas M, Karrer U, Lucas A, Klenerman P. Viral escape mechanisms--escapology taught by viruses. Int J Exp Pathol 2001;82:269-86. [PMID: 11703537 DOI: 10.1046/j.1365-2613.2001.00204.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 2.2] [Reference Citation Analysis]
346 Park SH, Rehermann B. Immune responses to HCV and other hepatitis viruses. Immunity 2014;40:13-24. [PMID: 24439265 DOI: 10.1016/j.immuni.2013.12.010] [Cited by in Crossref: 180] [Cited by in F6Publishing: 169] [Article Influence: 22.5] [Reference Citation Analysis]
347 Seifert U, Liermann H, Racanelli V, Halenius A, Wiese M, Wedemeyer H, Ruppert T, Rispeter K, Henklein P, Sijts A. Hepatitis C virus mutation affects proteasomal epitope processing. J Clin Invest. 2004;114:250-259. [PMID: 15254592 DOI: 10.1172/jci20985] [Cited by in Crossref: 3] [Cited by in F6Publishing: 60] [Article Influence: 0.2] [Reference Citation Analysis]
348 Inchauspé G, Feinstone S. Development of a hepatitis C virus vaccine. Clin Liver Dis. 2003;7:243-59, xi. [PMID: 12691469 DOI: 10.1016/s1089-3261(02)00067-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
349 Wang B, Schreiber G, Glynn S, Kleinman S, Wright D, Murphy E, Busch M; Retrovirus Epidemiology Donor Study1. Does prevalence of transfusion-transmissible viral infection reflect corresponding incidence in United States blood donors? Transfusion 2005;45:1089-96. [DOI: 10.1111/j.1537-2995.2005.00178.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 1.8] [Reference Citation Analysis]
350 Talal AH, Canchis PW, Jacobson IM. The HCV and HIV coinfected patient: What have we learned about pathophysiology? Curr Gastroenterol Rep 2002;4:15-22. [DOI: 10.1007/s11894-002-0033-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
351 Cerny A. Viral crosstalk: Who gets to say what first?: Viral crosstalk: Who gets to say what first? Hepatology 2002;35:1540-3. [DOI: 10.1002/hep.510350632] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
352 Locarnini SA. Mechanisms of drug resistance and novel approaches to therapy for chronic hepatitis C: Antiviral targets for hepatitis C virus. Journal of Gastroenterology and Hepatology 2002;17:S351-9. [DOI: 10.1046/j.1440-1746.17.s3.27.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
353 Delahooke TE. Hepatitis C: What is the nature of the problem? J Viral Hepat 2004;11 Suppl 1:5-11. [PMID: 15357857 DOI: 10.1111/j.1365-2893.2004.00569.x] [Reference Citation Analysis]
354 Alatrakchi N, Di Martino V, Thibault V, Autran B; ALT and IMMUNE-VIRC ANRS study groups. Strong CD4 Th1 responses to HIV and hepatitis C virus in HIV-infected long-term non-progressors co-infected with hepatitis C virus. AIDS 2002;16:713-7. [PMID: 11964527 DOI: 10.1097/00002030-200203290-00006] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 1.6] [Reference Citation Analysis]
355 Herrero Martínez E. Hepatitis B and hepatitis C co-infection in patients with HIV. Rev Med Virol 2001;11:253-70. [PMID: 11479931 DOI: 10.1002/rmv.323] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.0] [Reference Citation Analysis]
356 Zeremski M, Petrovic LM, Talal AH. The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection. J Viral Hepat 2007;0:070124051929001-???. [DOI: 10.1111/j.1365-2893.2006.00838.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 77] [Article Influence: 0.9] [Reference Citation Analysis]
357 Berzofsky JA, Ahlers JD, Janik J, Morris J, Oh S, Terabe M, Belyakov IM. Progress on new vaccine strategies against chronic viral infections. J Clin Invest 2004;114:450-62. [PMID: 15314679 DOI: 10.1172/JCI22674] [Cited by in Crossref: 4] [Cited by in F6Publishing: 39] [Article Influence: 0.2] [Reference Citation Analysis]
358 Weng PJ, Fu YM, Ding SX, Xu DP, Lin A, Yan WH. Elevation of plasma soluble human leukocyte antigen-G in patients with chronic hepatitis C virus infection. Hum Immunol. 2011;72:406-411. [PMID: 21377504 DOI: 10.1016/j.humimm.2011.02.008] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
359 Hartnell F, Esposito I, Swadling L, Brown A, Phetsouphanh C, de Lara C, Gentile C, Turner B, Dorrell L, Capone S, Folgori A, Barnes E, Klenerman P. Characterizing Hepatitis C Virus-Specific CD4+ T Cells Following Viral-Vectored Vaccination, Directly Acting Antivirals, and Spontaneous Viral Cure. Hepatology 2020;72:1541-55. [PMID: 32012325 DOI: 10.1002/hep.31160] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
360 Desselberger U. Hepatitis C virus: new advances trap an age-old killer. Future Virology 2006;1:703-8. [DOI: 10.2217/17460794.1.6.703] [Reference Citation Analysis]
361 Fournillier A, Wychowski C, Boucreux D, Baumert TF, Meunier JC, Jacobs D, Muguet S, Depla E, Inchauspé G. Induction of hepatitis C virus E1 envelope protein-specific immune response can be enhanced by mutation of N-glycosylation sites. J Virol 2001;75:12088-97. [PMID: 11711599 DOI: 10.1128/JVI.75.24.12088-12097.2001] [Cited by in Crossref: 60] [Cited by in F6Publishing: 31] [Article Influence: 2.9] [Reference Citation Analysis]
362 Matsui M, Moriya O, Belladonna ML, Kamiya S, Lemonnier FA, Yoshimoto T, Akatsuka T. Adjuvant activities of novel cytokines, interleukin-23 (IL-23) and IL-27, for induction of hepatitis C virus-specific cytotoxic T lymphocytes in HLA-A*0201 transgenic mice. J Virol 2004;78:9093-104. [PMID: 15308705 DOI: 10.1128/JVI.78.17.9093-9104.2004] [Cited by in Crossref: 68] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
363 Vigón L, Vázquez-Morón S, Berenguer J, González-García J, Jiménez-Sousa MÁ, Guardiola JM, Crespo M, de Los Santos I, Von Wichmann MA, Carrero A, Yélamos MB, Gómez J, Resino S, Martínez I; GESIDA 3603b Cohort Study Group. Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR. Sci Rep 2019;9:12163. [PMID: 31434968 DOI: 10.1038/s41598-019-48592-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
364 Castello G, Costantini S, Scala S. Targeting the inflammation in HCV-associated hepatocellular carcinoma: a role in the prevention and treatment. J Transl Med 2010;8:109. [PMID: 21047421 DOI: 10.1186/1479-5876-8-109] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
365 Walewski JL, Keller TR, Stump DD, Branch AD. Evidence for a new hepatitis C virus antigen encoded in an overlapping reading frame. RNA. 2001;7:710-721. [PMID: 11350035 DOI: 10.1017/s1355838201010111] [Cited by in Crossref: 188] [Cited by in F6Publishing: 78] [Article Influence: 9.0] [Reference Citation Analysis]
366 Berger A, Giroglou T, Leutz A, Ogbomo H, Pfaff K, Teuber G, Cinatl J, van Laer D, Doerr HW. Measurements of HCV neutralizing antibodies and of HCV-specific CD4+ and CD8+ cells using hepatitis C virus pseudo-particles (HCVpp). J Clin Virol 2009;46:55-60. [PMID: 19560398 DOI: 10.1016/j.jcv.2009.05.036] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
367 van de Laar TJ, Matthews GV, Prins M, Danta M. Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection. AIDS. 2010;24:1799-1812. [PMID: 20601854 DOI: 10.1097/qad.0b013e32833c11a5] [Cited by in Crossref: 180] [Cited by in F6Publishing: 69] [Article Influence: 16.4] [Reference Citation Analysis]
368 Han JW, Sung PS, Hong SH, Lee H, Koh JY, Lee H, White S, Maslow JN, Weiner DB, Park SH, Jeong M, Heo J, Ahn SH, Shin EC. IFNL3-adjuvanted HCV DNA vaccine reduces regulatory T cell frequency and increases virus-specific T cell responses. J Hepatol 2020;73:72-83. [PMID: 32088322 DOI: 10.1016/j.jhep.2020.02.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
369 Rahman MM, Badruzzaman A, Altaf Hossain FM, Husna A, Bari AM, Eo SK. The promise of 4-1BB (CD137) mediated immunomodulation and immunotherapy for viral diseases. Future Virology 2017;12:361-72. [DOI: 10.2217/fvl-2016-0100] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
370 Yoon JC, Shiina M, Ahlenstiel G, Rehermann B. Natural killer cell function is intact after direct exposure to infectious hepatitis C virions. Hepatology. 2009;49:12-21. [PMID: 19085909 DOI: 10.1002/hep.22624] [Cited by in Crossref: 82] [Cited by in F6Publishing: 78] [Article Influence: 6.3] [Reference Citation Analysis]
371 Phelps CC, Walker CM, Honegger JR. Where to Next? Research Directions after the First Hepatitis C Vaccine Efficacy Trial. Viruses 2021;13:1351. [PMID: 34372558 DOI: 10.3390/v13071351] [Reference Citation Analysis]
372 Rausch JW, Le Grice SFJ. Characterizing the Latent HIV-1 Reservoir in Patients with Viremia Suppressed on cART: Progress, Challenges, and Opportunities. Curr HIV Res 2020;18:99-113. [PMID: 31889490 DOI: 10.2174/1570162X18666191231105438] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
373 Roulland S, Suarez F, Hermine O, Nadel B. Pathophysiological aspects of memory B-cell development. Trends Immunol 2008;29:25-33. [PMID: 18061541 DOI: 10.1016/j.it.2007.10.005] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
374 Weseslindtner L, Neumann-haefelin C, Viazov S, Haberstroh A, Kletzmayr J, Aberle JH, Timm J, Ross SR, Klauser-braun R, Baumert TF, Roggendorf M, Thimme R, Holzmann H. Acute infection with a single hepatitis C virus strain in dialysis patients: Analysis of adaptive immune response and viral variability. Journal of Hepatology 2009;50:693-704. [DOI: 10.1016/j.jhep.2008.11.023] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
375 Hoofnagle JH. Course and outcome of hepatitis C. Hepatology. 2002;36:S21-S29. [PMID: 12407573 DOI: 10.1053/jhep.2002.36227] [Cited by in Crossref: 94] [Cited by in F6Publishing: 362] [Article Influence: 4.7] [Reference Citation Analysis]
376 Pawlotsky J, Mchutchison JG. Hepatitis C. Development of new drugs and clinical trials: Promises and pitfalls. Summary of an AASLD hepatitis single topic conference, Chicago, IL, February 27-March 1, 2003. Hepatology 2004;39:554-67. [DOI: 10.1002/hep.20065] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 2.5] [Reference Citation Analysis]
377 Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet. 2003;362:2095-2100. [PMID: 14697814 DOI: 10.1016/s0140-6736(03)15109-4] [Cited by in Crossref: 604] [Cited by in F6Publishing: 199] [Article Influence: 33.6] [Reference Citation Analysis]
378 Yu M, Dai C, Chiu C, Lee L, Lin Z, Chen S, Hsieh M, Wang L, Chen C, Chuang W, Chang W. Tumor necrosis factor α promoter polymorphisms at position −308 in Taiwanese chronic hepatitis C patients treated with interferon-alpha. Antiviral Research 2003;59:35-40. [DOI: 10.1016/s0166-3542(03)00029-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
379 Pham TN, Mercer SE, Michalak TI. Chronic hepatitis C and persistent occult hepatitis C virus infection are characterized by distinct immune cell cytokine expression profiles. J Viral Hepat. 2009;16:547-556. [PMID: 19215578 DOI: 10.1111/j.1365-2893.2009.01092.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.0] [Reference Citation Analysis]
380 Sugimoto K, Ikeda F, Stadanlick J, Nunes FA, Alter HJ, Chang KM. Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection. Hepatology 2003;38:1437-48. [PMID: 14647055 DOI: 10.1016/j.hep.2003.09.026] [Cited by in Crossref: 21] [Cited by in F6Publishing: 127] [Article Influence: 1.1] [Reference Citation Analysis]
381 Pasetto A, Frelin L, Aleman S, Holmström F, Brass A, Ahlén G, Brenndörfer ED, Lohmann V, Bartenschlager R, Sällberg M, Bertoletti A, Chen M. TCR-redirected human T cells inhibit hepatitis C virus replication: hepatotoxic potential is linked to antigen specificity and functional avidity. J Immunol 2012;189:4510-9. [PMID: 23024278 DOI: 10.4049/jimmunol.1201613] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
382 Jagannathan P, Osborne CM, Royce C, Manion MM, Tilton JC, Li L, Fischer S, Hallahan CW, Metcalf JA, McLaughlin M, Pipeling M, McDyer JF, Manley TJ, Meier JL, Altman JD, Hertel L, Davey RT Jr, Connors M, Migueles SA. Comparisons of CD8+ T cells specific for human immunodeficiency virus, hepatitis C virus, and cytomegalovirus reveal differences in frequency, immunodominance, phenotype, and interleukin-2 responsiveness. J Virol 2009;83:2728-42. [PMID: 19129459 DOI: 10.1128/JVI.02128-08] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
383 Shin EC, Park SH, Demino M, Nascimbeni M, Mihalik K, Major M, Veerapu NS, Heller T, Feinstone SM, Rice CM, Rehermann B. Delayed induction, not impaired recruitment, of specific CD8⁺ T cells causes the late onset of acute hepatitis C. Gastroenterology 2011;141:686-95, 695.e1. [PMID: 21699897 DOI: 10.1053/j.gastro.2011.05.006] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 3.9] [Reference Citation Analysis]
384 Maasoumy B, Wedemeyer H. Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol. 2012;26:401-412. [PMID: 23199500 DOI: 10.1016/j.bpg.2012.09.009] [Cited by in Crossref: 148] [Cited by in F6Publishing: 142] [Article Influence: 16.4] [Reference Citation Analysis]
385 Rosen HR, McHutchison JG, Conrad AJ, Lentz JJ, Marousek G, Rose SL, Zaman A, Taylor K, Chou S. Tumor necrosis factor genetic polymorphisms and response to antiviral therapy in patients with chronic hepatitis C. Am J Gastroenterol. 2002;97:714-720. [PMID: 11922568 DOI: 10.1111/j.1572-0241.2002.05552.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 2.0] [Reference Citation Analysis]
386 Vickerman P, Grebely J, Dore GJ, Sacks-Davis R, Page K, Thomas DL, Osburn WO, Cox AL, Aitken CK, Hickman M, Hellard M; International Collaboration of Incident HIV and Hepatitis C in Injecting Cohorts (InC3). The more you look, the more you find: effects of hepatitis C virus testing interval on reinfection incidence and clearance and implications for future vaccine study design. J Infect Dis 2012;205:1342-50. [PMID: 22457292 DOI: 10.1093/infdis/jis213] [Cited by in Crossref: 54] [Cited by in F6Publishing: 48] [Article Influence: 5.4] [Reference Citation Analysis]
387 Kraus S, Kleines M, Albers J, Blohm L, Piechotta G, Püttmann C, Barth S, Nähring J, Nebling E. Quantitative measurement of human anti-HCV Core immunoglobulins on an electrical biochip platform. Biosensors and Bioelectronics 2011;26:1895-901. [DOI: 10.1016/j.bios.2010.03.026] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
388 Gigi E, Raptopoulou-Gigi M, Kalogeridis A, Masiou S, Orphanou E, Vrettou E, Lalla TH, Sinakos E, Tsapas V. Cytokine mRNA expression in hepatitis C virus infection: TH1 predominance in patients with chronic hepatitis C and TH1-TH2 cytokine profile in subjects with self-limited disease. J Viral Hepat. 2008;15:145-154. [PMID: 18184198 DOI: 10.1111/j.1365-2893.2007.00908.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 15] [Article Influence: 0.4] [Reference Citation Analysis]
389 Walker CM. Adaptive immunity to the hepatitis C virus. Adv Virus Res 2010;78:43-86. [PMID: 21040831 DOI: 10.1016/B978-0-12-385032-4.00002-1] [Cited by in Crossref: 51] [Cited by in F6Publishing: 38] [Article Influence: 4.6] [Reference Citation Analysis]
390 Shen C, Gupta P, Xu X, Sanyal A, Rinaldo C, Seaberg E, Margolick JB, Martinez-Maza O, Chen Y. Transmission and evolution of hepatitis C virus in HCV seroconverters in HIV infected subjects. Virology 2014;449:339-49. [PMID: 24418568 DOI: 10.1016/j.virol.2013.11.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
391 Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol. 2005;5:215-229. [PMID: 15738952 DOI: 10.1038/nri1573] [Cited by in Crossref: 1133] [Cited by in F6Publishing: 1075] [Article Influence: 66.6] [Reference Citation Analysis]
392 Pallarés C, Carvalho-Gomes Â, Hontangas V, Conde I, Di Maira T, Aguilera V, Benlloch S, Berenguer M, López-Labrador FX. Performance of the OraQuick Hepatitis C virus antibody test in oral fluid and fingerstick blood before and after treatment-induced viral clearance. J Clin Virol 2018;102:77-83. [PMID: 29525634 DOI: 10.1016/j.jcv.2018.02.016] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
393 Auffermann-gretzinger S, Keeffe EB, Levy S. Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection. Blood 2001;97:3171-6. [DOI: 10.1182/blood.v97.10.3171] [Cited by in Crossref: 233] [Cited by in F6Publishing: 96] [Article Influence: 11.1] [Reference Citation Analysis]
394 Pfafferott K, Gaudieri S, Ulsenheimer A, James I, Heeg M, Nolan D, John M, Rauch A, Mallal S, Lucas A, Klenerman P, Diepolder HM, Lucas M. Constrained pattern of viral evolution in acute and early HCV infection limits viral plasticity. PLoS One 2011;6:e16797. [PMID: 21347433 DOI: 10.1371/journal.pone.0016797] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
395 Posthouwer D, Fischer K, van Erpecum KJ, Mauser-Bunschoten EP. The natural history of childhood-acquired hepatitis C infection in patients with inherited bleeding disorders. Transfusion. 2006;46:1360-1366. [PMID: 16934072 DOI: 10.1111/j.1537-2995.2006.00903.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
396 Gehring S, Gregory SH, Wintermeyer P, Aloman C, Wands JR. Generation of immune responses against hepatitis C virus by dendritic cells containing NS5 protein-coated microparticles. Clin Vaccine Immunol 2009;16:163-71. [PMID: 19091993 DOI: 10.1128/CVI.00287-08] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
397 Neau D, Jouvencel A, Legrand E, Trimoulet P, Galperine T, Chitty I, Ventura M, Le Bail B, Morlat P, Lacut J, Ragnaud J, Dupon M, Fleury H, Lafon M. Hepatitis C virus genetic variability in 52 human immunodeficiency virus-coinfected patients. J Med Virol 2003;71:41-8. [DOI: 10.1002/jmv.10451] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
398 Bailey J. An assessment of the use of chimpanzees in hepatitis C research past, present and future: 1. Validity of the chimpanzee model. Altern Lab Anim 2010;38:387-418. [PMID: 21105756 DOI: 10.1177/026119291003800501] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
399 Kaplan DE, Sugimoto K, Ikeda F, Stadanlick J, Valiga M, Shetty K, Reddy KR, Chang KM. T-cell response relative to genotype and ethnicity during antiviral therapy for chronic hepatitis C. Hepatology 2005;41:1365-75. [PMID: 15915458 DOI: 10.1002/hep.20706] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 2.5] [Reference Citation Analysis]
400 Miyaki E, Hiraga N, Imamura M, Uchida T, Kan H, Tsuge M, Abe-Chayama H, Hayes CN, Makokha GN, Serikawa M, Aikata H, Ochi H, Ishida Y, Tateno C, Ohdan H, Chayama K. Interferon alpha treatment stimulates interferon gamma expression in type I NKT cells and enhances their antiviral effect against hepatitis C virus. PLoS One 2017;12:e0172412. [PMID: 28253324 DOI: 10.1371/journal.pone.0172412] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
401 Erickson AL, Kimura Y, Igarashi S, Eichelberger J, Houghton M, Sidney J, McKinney D, Sette A, Hughes AL, Walker CM. The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity. 2001;15:883-895. [PMID: 11754811 DOI: 10.1016/s1074-7613(01)00245-x] [Cited by in Crossref: 305] [Cited by in F6Publishing: 143] [Article Influence: 15.3] [Reference Citation Analysis]
402 Mohsen AH, Easterbrook P, Taylor CB, Norris S. Hepatitis C and HIV-1 coinfection. Gut 2002;51:601-8. [PMID: 12235089 DOI: 10.1136/gut.51.4.601] [Cited by in Crossref: 60] [Cited by in F6Publishing: 59] [Article Influence: 3.0] [Reference Citation Analysis]
403 Chuang WC, Sarkodie F, Brown CJ, Owusu-Ofori S, Brown J, Li C, Navarrete C, Klenerman P, Allain JP. Protective effect of HLA-B57 on HCV genotype 2 infection in a West African population. J Med Virol. 2007;79:724-733. [PMID: 17546694 DOI: 10.1002/jmv.20848] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 2.5] [Reference Citation Analysis]
404 Daar ES, Lynn H, Donfield S, Gomperts E, Hilgartner MW, Hoots WK, Chernoff D, Arkin S, Wong WY, Winkler CA; Hemophilia Growth and Development Study. Relation between HIV-1 and hepatitis C viral load in patients with hemophilia. J Acquir Immune Defic Syndr 2001;26:466-72. [PMID: 11391167 DOI: 10.1097/00126334-200104150-00011] [Cited by in Crossref: 50] [Cited by in F6Publishing: 58] [Article Influence: 2.4] [Reference Citation Analysis]
405 Sarkodie F, Adarkwa M, Adu-Sarkodie Y, Candotti D, Acheampong JW, Allain JP. Screening for viral markers in volunteer and replacement blood donors in West Africa. Vox Sang 2001;80:142-7. [PMID: 11840974 DOI: 10.1046/j.1423-0410.2001.00023.x] [Cited by in Crossref: 79] [Cited by in F6Publishing: 80] [Article Influence: 4.0] [Reference Citation Analysis]
406 Vickerman P, Hickman M, Judd A. Modelling the impact on Hepatitis C transmission of reducing syringe sharing: London case study. International Journal of Epidemiology 2007;36:396-405. [DOI: 10.1093/ije/dyl276] [Cited by in Crossref: 69] [Cited by in F6Publishing: 60] [Article Influence: 4.6] [Reference Citation Analysis]
407 Lauer GM, Ouchi K, Chung RT, Nguyen TN, Day CL, Purkis DR, Reiser M, Kim AY, Lucas M, Klenerman P. Comprehensive analysis of CD8(+)-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities. J Virol. 2002;76:6104-6113. [PMID: 12021343 DOI: 10.1128/jvi.76.12.6104-6113.2002] [Cited by in Crossref: 144] [Cited by in F6Publishing: 61] [Article Influence: 7.2] [Reference Citation Analysis]
408 Wiesner RH. Is there disease progression in patients who are hepatitis C virus antibody-positive and hepatitis C virus RNA-seronegative? Hepatology 2008;48:1734-6. [DOI: 10.1002/hep.22728] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
409 Comar M, Dal Molin G, D'Agaro P, Crocè SL, Tiribelli C, Campello C. HBV, HCV, and TTV detection by in situ polymerase chain reaction could reveal occult infection in hepatocellular carcinoma: comparison with blood markers. J Clin Pathol. 2006;59:526-529. [PMID: 16537674 DOI: 10.1136/jcp.2005.033050] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 1.8] [Reference Citation Analysis]
410 Ruys TA, Nanlohy NM, van den Berg CH, Hassink E, Beld M, van de Laar T, Bruisten S, Wit F, Krol A, Prins M, Lange J, van Baarle D. HCV-specific T-cell responses in injecting drug users: evidence for previous exposure to HCV and a role for CD4+ T cells focussing on nonstructural proteins in viral clearance. J Viral Hepat 2008;15:409-20. [PMID: 18221302 DOI: 10.1111/j.1365-2893.2007.00963.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
411 Folgori A, Capone S, Ruggeri L, Meola A, Sporeno E, Ercole BB, Pezzanera M, Tafi R, Arcuri M, Fattori E. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med. 2006;12:190-197. [PMID: 16462801 DOI: 10.1038/nm1353] [Cited by in Crossref: 237] [Cited by in F6Publishing: 220] [Article Influence: 14.8] [Reference Citation Analysis]
412 Cox AL, Mosbruger T, Mao Q, Liu Z, Wang XH, Yang HC, Sidney J, Sette A, Pardoll D, Thomas DL, Ray SC. Cellular immune selection with hepatitis C virus persistence in humans. J Exp Med. 2005;201:1741-1752. [PMID: 15939790 DOI: 10.1084/jem.20050121] [Cited by in Crossref: 225] [Cited by in F6Publishing: 216] [Article Influence: 13.2] [Reference Citation Analysis]
413 Burke KP, Cox AL. Hepatitis C virus evasion of adaptive immune responses: a model for viral persistence. Immunol Res. 2010;47:216-227. [PMID: 20066508 DOI: 10.1007/s12026-009-8152-3] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 4.0] [Reference Citation Analysis]
414 Umemura T, Wang RY, Schechterly C, Shih JW, Kiyosawa K, Alter HJ. Quantitative analysis of anti-hepatitis C virus antibody-secreting B cells in patients with chronic hepatitis C. Hepatology 2006;43:91-9. [DOI: 10.1002/hep.20917] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 1.5] [Reference Citation Analysis]
415 Tobler LH, Stramer SL, Lee SR, Masecar BL, Peterson JE, Davis EA, Andrews WE, Brodsky JP, Kleinman SH, Phelps BH, Busch MP. Impact of HCV 3.0 EIA relative to HCV 2.0 EIA on blood-donor screening: IMPACT OF HCV 3.0 EIA ON VOLUNTEER DONOR SCREENING. Transfusion 2003;43:1452-9. [DOI: 10.1046/j.1537-2995.2003.00521.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 1.7] [Reference Citation Analysis]
416 Sugden PB, Cameron B, Bull R, White PA, Lloyd AR. Occult infection with hepatitis C virus: friend or foe? Immunol Cell Biol 2012;90:763-73. [PMID: 22546735 DOI: 10.1038/icb.2012.20] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
417 Henderson DK. Managing occupational risks for hepatitis C transmission in the health care setting. Clin Microbiol Rev 2003;16:546-68. [PMID: 12857782 DOI: 10.1128/CMR.16.3.546-568.2003] [Cited by in Crossref: 70] [Cited by in F6Publishing: 16] [Article Influence: 3.7] [Reference Citation Analysis]
418 Ismail N, Fish GE, Smith MB. Laboratory evaluation of a fully automated chemiluminescence immunoassay for rapid detection of HBsAg, antibodies to HBsAg, and antibodies to hepatitis C virus. J Clin Microbiol. 2004;42:610-617. [PMID: 14766824 DOI: 10.1128/jcm.42.2.610-617.2004] [Cited by in Crossref: 32] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
419 Herrero-martínez E, Sabin CA, Lee CA, Jones IM, Pillay D, Emery VC. The effect of highly active antiretroviral therapy for HIV on the anti-HCV specific humoral immune response: Antiretroviral Therapy and Anti-HCV Humoral Immunity. J Med Virol 2004;72:187-93. [DOI: 10.1002/jmv.10578] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
420 Klade C, Kubitschke A, Stauber R, Meyer M, Zinke S, Wiegand J, Zauner W, Aslan N, Lehmann M, Cornberg M, Manns M, Reisner P, Wedemeyer H. Hepatitis C virus-specific T cell responses against conserved regions in recovered patients. Vaccine 2009;27:3099-108. [DOI: 10.1016/j.vaccine.2009.02.088] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
421 Matsui M, Moriya O, Abdel-Aziz N, Matsuura Y, Miyamura T, Akatsuka T. Induction of hepatitis C virus-specific cytotoxic T lymphocytes in mice by immunization with dendritic cells transduced with replication-defective recombinant adenovirus. Vaccine. 2002;21:211-220. [PMID: 12450696 DOI: 10.1016/S0264-410X(02)00460-7] [Cited by in Crossref: 27] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
422 Picchio GR, Baré PC, Descalzi VI, Bussy MV, Soria SM, Raffa MP, Mazzencio NE, Etchehun S, Cámera JA, Mosier DE. High prevalence of infection with a single hepatitis C virus genotype in a small rural community of Argentina. Liver Int. 2006;26:660-665. [PMID: 16842321 DOI: 10.1111/j.1478-3231.2006.01290.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
423 Kamal SM. Acute hepatitis C: a systematic review. Am J Gastroenterol 2008;103:1283-97; quiz 1298. [PMID: 18477352 DOI: 10.1111/j.1572-0241.2008.01825.x] [Cited by in Crossref: 103] [Cited by in F6Publishing: 81] [Article Influence: 7.4] [Reference Citation Analysis]
424 Barrett S, Sweeney M, Crowe J. Host immune responses in hepatitis C virus clearance. Eur J Gastroenterol Hepatol. 2005;17:1089-1097. [PMID: 16148555 DOI: 10.1097/00042737-200510000-00013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
425 Michalak TI, Pham TN, Mulrooney-cousins PM. Molecular diagnosis of occult HCV and HBV infections. Future Virology 2007;2:451-65. [DOI: 10.2217/17460794.2.5.451] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
426 Crosignani A, Riva A, Della Bella S. Analysis of peripheral blood dendritic cells as a non-invasive tool in the follow-up of patients with chronic hepatitis C. World J Gastroenterol 2016; 22(4): 1393-1404 [PMID: 26819508 DOI: 10.3748/wjg.v22.i4.1393] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
427 Kaplan DE, Sugimoto K, Newton K, Valiga ME, Ikeda F, Aytaman A, Nunes FA, Lucey MR, Vance BA, Vonderheide RH. Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C. Gastroenterology. 2007;132:654-666. [PMID: 17258733 DOI: 10.1053/j.gastro.2006.11.044] [Cited by in Crossref: 123] [Cited by in F6Publishing: 113] [Article Influence: 7.7] [Reference Citation Analysis]
428 Sugimoto K, Kaplan DE, Ikeda F, Ding J, Schwartz J, Nunes FA, Alter HJ, Chang KM. Strain-specific T-cell suppression and protective immunity in patients with chronic hepatitis C virus infection. J Virol. 2005;79:6976-6983. [PMID: 15890937 DOI: 10.1128/jvi.79.11.6976-6983.2005] [Cited by in Crossref: 36] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
429 Ramírez S, Pérez-Del-Pulgar S, Forns X. Virology and pathogenesis of hepatitis C virus recurrence. Liver Transpl. 2008;14 Suppl 2:S27-S35. [PMID: 18825723 DOI: 10.1002/lt.21644] [Cited by in Crossref: 47] [Cited by in F6Publishing: 34] [Article Influence: 3.6] [Reference Citation Analysis]
430 Freeman AJ, Marinos G, Ffrench RA, Lloyd AR. Immunopathogenesis of hepatitis C virus infection. Immunol Cell Biol. 2001;79:515-536. [PMID: 11903612 DOI: 10.1046/j.1440-1711.2001.01036.x] [Cited by in Crossref: 62] [Cited by in F6Publishing: 61] [Article Influence: 3.1] [Reference Citation Analysis]
431 Lewis-Ximenez LL, Lauer GM, Schulze Zur Wiesch J, de Sousa PS, Ginuino CF, Paranhos-Baccalá G, Ulmer H, Pfeiffer KP, Goebel G, Pereira JL, Mendes de Oliveira J, Yoshida CF, Lampe E, Velloso CE, Alves Pinto M, Coelho HS, Almeida AJ, Fernandes CA, Kim AY, Strasak AM. Prospective follow-up of patients with acute hepatitis C virus infection in Brazil. Clin Infect Dis 2010;50:1222-30. [PMID: 20235831 DOI: 10.1086/651599] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
432 Sautto G, Mancini N, Solforosi L, Diotti RA, Clementi M, Burioni R. HCV proteins and immunoglobulin variable gene (IgV) subfamilies in HCV-induced type II mixed cryoglobulinemia: a concurrent pathogenetic role. Clin Dev Immunol 2012;2012:705013. [PMID: 22690241 DOI: 10.1155/2012/705013] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
433 Balasiddaiah A, Davanian H, Aleman S, Pasetto A, Frelin L, Sällberg M, Lohmann V, Koh S, Bertoletti A, Chen M. Hepatitis C Virus-Specific T Cell Receptor mRNA-Engineered Human T Cells: Impact of Antigen Specificity on Functional Properties. J Virol 2017;91:e00010-17. [PMID: 28228595 DOI: 10.1128/JVI.00010-17] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
434 Sacks-Davis R, Pedrana AE, Scott N, Doyle JS, Hellard ME. Eliminating HIV/HCV co-infection in gay and bisexual men: is it achievable through scaling up treatment? Expert Rev Anti Infect Ther 2018;16:411-22. [PMID: 29722275 DOI: 10.1080/14787210.2018.1471355] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
435 Cameron B, Galbraith S, Li H, Lloyd A; the HITS investigators. Correlates and characteristics of hepatitis C virus-specific T-cell immunity in exposed uninfected high-risk prison inmates. J Viral Hepat 2013;20:e96-e106. [DOI: 10.1111/jvh.12016] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
436 Thammanichanond D, Moneer S, Yotnda P, Aitken C, Earnest-silveira L, Jackson D, Hellard M, Mccluskey J, Torresi J, Bharadwaj M. Fiber-modified recombinant adenoviral constructs encoding hepatitis C virus proteins induce potent HCV-specific T cell response. Clinical Immunology 2008;128:329-39. [DOI: 10.1016/j.clim.2008.04.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
437 Hahn YS. Subversion of immune responses by hepatitis C virus: immunomodulatory strategies beyond evasion? Curr Opin Immunol. 2003;15:443-449. [PMID: 12900277 DOI: 10.1016/s0952-7915(03)00076-1] [Cited by in Crossref: 49] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
438 Park SH, Veerapu NS, Shin EC, Biancotto A, McCoy JP, Capone S, Folgori A, Rehermann B. Subinfectious hepatitis C virus exposures suppress T cell responses against subsequent acute infection. Nat Med 2013;19:1638-42. [PMID: 24270546 DOI: 10.1038/nm.3408] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 4.0] [Reference Citation Analysis]
439 Heller T, Werner JM, Rahman F, Mizukoshi E, Sobao Y, Gordon AM, Sheets A, Sherker AH, Kessler E, Bean KS, Herrine SK, Stevens M, Schmitt J, Rehermann B. Occupational exposure to hepatitis C virus: early T-cell responses in the absence of seroconversion in a longitudinal cohort study. J Infect Dis 2013;208:1020-5. [PMID: 23801608 DOI: 10.1093/infdis/jit270] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
440 Eisen-Vandervelde AL, Yao ZQ, Hahn YS. The molecular basis of HCV-mediated immune dysregulation. Clin Immunol 2004;111:16-21. [PMID: 15093547 DOI: 10.1016/j.clim.2003.12.003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
441 Soriano V, Mocroft A, Rockstroh J, Ledergerber B, Knysz B, Chaplinskas S, Peters L, Karlsson A, Katlama C, Toro C. Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. J Infect Dis. 2008;198:1337-1344. [PMID: 18767985 DOI: 10.1086/592171] [Cited by in Crossref: 112] [Cited by in F6Publishing: 113] [Article Influence: 8.0] [Reference Citation Analysis]
442 Takaki A, Yagi T, Yamamoto K. Contradictory immune response in post liver transplantation hepatitis B and C. Int J Inflam 2014;2014:814760. [PMID: 25215259 DOI: 10.1155/2014/814760] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
443 Racanelli V, Frassanito MA, Leone P, Galiano M, De Re V, Silvestris F, Dammacco F. Antibody production and in vitro behavior of CD27-defined B-cell subsets: persistent hepatitis C virus infection changes the rules. J Virol. 2006;80:3923-3934. [PMID: 16571809 DOI: 10.1128/jvi.80.8.3923-3934.2006] [Cited by in Crossref: 58] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
444 Crotty S, Ahmed R. Immunological memory in humans. Seminars in Immunology 2004;16:197-203. [DOI: 10.1016/j.smim.2004.02.008] [Cited by in Crossref: 160] [Cited by in F6Publishing: 147] [Article Influence: 8.9] [Reference Citation Analysis]
445 Zaily DG, Marlen CF, Santiago DC, Gillian MD, Carmen VS, Zurina CE, Enrique R AS, Liz AL, Lisset GF, Sacha LDV, Elena FB. Clinical Evaluation of Terap C Vaccine in Combined Treatment with Interferon and Ribavirin in Patients with Hepatitis C. Curr Ther Res Clin Exp 2017;85:20-8. [PMID: 29158855 DOI: 10.1016/j.curtheres.2017.04.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
446 Shoukry NH. Hepatitis C Vaccines, Antibodies, and T Cells. Front Immunol 2018;9:1480. [PMID: 30002657 DOI: 10.3389/fimmu.2018.01480] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 10.3] [Reference Citation Analysis]
447 Samuel D, Forns X, Berenguer M, Trautwein C, Burroughs A, Rizzetto M, Trepo C. Report of the Monothematic EASL Conference on Liver Transplantation for Viral Hepatitis. Journal of Hepatology 2006;45:127-43. [DOI: 10.1016/j.jhep.2006.05.001] [Cited by in Crossref: 129] [Cited by in F6Publishing: 110] [Article Influence: 8.1] [Reference Citation Analysis]
448 Shiina M, Rehermann B. Cell culture-produced hepatitis C virus impairs plasmacytoid dendritic cell function. Hepatology. 2008;47:385-395. [PMID: 18064579 DOI: 10.1002/hep.21996] [Cited by in Crossref: 73] [Cited by in F6Publishing: 82] [Article Influence: 5.2] [Reference Citation Analysis]
449 Kamal SM, Amin A, Madwar M, Graham CS, He Q, Al Tawil A, Rasenack J, Nakano T, Robertson B, Ismail A, Koziel MJ. Cellular immune responses in seronegative sexual contacts of acute hepatitis C patients. J Virol 2004;78:12252-8. [PMID: 15507612 DOI: 10.1128/JVI.78.22.12252-12258.2004] [Cited by in Crossref: 65] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
450 Shi L, Liu S, Fan G, Sheng L, Ren H, Yuan Y. Effective Induction of Type 1 Cytotoxic T Cell Responses in Mice with DNA Vaccine Encoding Two Hepatitis C Virus Cytotoxic T Lymphocyte Epitopes. Viral Immunology 2006;19:702-11. [DOI: 10.1089/vim.2006.19.702] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
451 Alvarez-Lajonchere L, Dueñas-Carrera S. Complete definition of immunological correlates of protection and clearance of hepatitis C virus infection: a relevant pending task for vaccine development. Int Rev Immunol 2012;31:223-42. [PMID: 22587022 DOI: 10.3109/08830185.2012.680552] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
452 Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, Wieland SF, Uprichard SL, Wakita T, Chisari FV. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci USA. 2005;102:9294-9299. [PMID: 15939869 DOI: 10.1073/pnas.0503596102] [Cited by in Crossref: 1374] [Cited by in F6Publishing: 1335] [Article Influence: 80.8] [Reference Citation Analysis]
453 Dustin LB, Cashman SB, Laidlaw SM. Immune control and failure in HCV infection--tipping the balance. J Leukoc Biol. 2014;96:535-548. [PMID: 25015956 DOI: 10.1189/jlb.4ri0214-126r] [Cited by in Crossref: 32] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
454 Bernardin F, Stramer SL, Rehermann B, Page-Shafer K, Cooper S, Bangsberg DR, Hahn J, Tobler L, Busch M, Delwart E. High levels of subgenomic HCV plasma RNA in immunosilent infections. Virology 2007;365:446-56. [PMID: 17493654 DOI: 10.1016/j.virol.2007.04.003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
455 Pawlotsky J, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, Marra F, Puoti M, Wedemeyer H. EASL recommendations on treatment of hepatitis C: Final update of the series☆. Journal of Hepatology 2020;73:1170-218. [DOI: 10.1016/j.jhep.2020.08.018] [Cited by in Crossref: 113] [Cited by in F6Publishing: 102] [Article Influence: 56.5] [Reference Citation Analysis]
456 Rothman AL, Morishima C, Bonkovsky HL, Polyak SJ, Ray R, Di Bisceglie AM, Lindsay KL, Malet PF, Chang M, Gretch DR, Sullivan DG, Bhan AK, Wright EC, Koziel MJ; HALT-C Trial Group. Associations among clinical, immunological, and viral quasispecies measurements in advanced chronic hepatitis C. Hepatology 2005;41:617-25. [PMID: 15726656 DOI: 10.1002/hep.20581] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 1.5] [Reference Citation Analysis]
457 Zubkova I, Choi YH, Chang E, Pirollo K, Uren T, Watanabe H, Wells F, Kachko A, Krawczynski K, Major ME. T-cell vaccines that elicit effective immune responses against HCV in chimpanzees may create greater immune pressure for viral mutation. Vaccine. 2009;27:2594-2602. [PMID: 19428866 DOI: 10.1016/j.vaccine.2009.02.045] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
458 Quiroga JA, Llorente S, Castillo I, Rodríguez-Iñigo E, Pardo M, Carreño V. Cellular immune responses associated with occult hepatitis C virus infection of the liver. J Virol 2006;80:10972-9. [PMID: 17071928 DOI: 10.1128/JVI.00852-06] [Cited by in Crossref: 41] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
459 Waghray A, O'Shea R, Pai R, Menon KV. Hepatocellular carcinoma complicating recurrent hepatitis C after liver transplantation. Hepatology 2013;58:1854-5. [PMID: 23744815 DOI: 10.1002/hep.26548] [Reference Citation Analysis]
460 Nishimura M, Takaki A, Tamaki N, Maruyama T, Onishi H, Kobayashi S, Nouso K, Yasunaka T, Koike K, Hagihara H. Serum oxidative-anti-oxidative stress balance is dysregulated in patients with hepatitis C virus-related hepatocellular carcinoma. Hepatol Res. 2013;43:1078-1092. [PMID: 23363268 DOI: 10.1111/hepr.12048] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
461 Maasoumy B, Bremer B, Raupach R, Lehmann P, Manns MP, Cornberg M, Wedemeyer H. How to interpret borderline HCV antibody test results: a comparative study investigating four different anti-HCV assays. Viral Immunol 2014;27:7-13. [PMID: 24494968 DOI: 10.1089/vim.2013.0064] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
462 Rivière Y, Montange T, Janvier G, Marnata C, Durrieu L, Chaix ML, Isaguliants M, Launay O, Bresson JL, Pol S. Hepatitis C virus-specific cellular immune responses in individuals with no evidence of infection. Virol J 2012;9:76. [PMID: 22455516 DOI: 10.1186/1743-422X-9-76] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
463 Maheshwari A, Ray S, Thuluvath PJ. Acute hepatitis C. Lancet 2008;372:321-32. [PMID: 18657711 DOI: 10.1016/S0140-6736(08)61116-2] [Cited by in Crossref: 177] [Cited by in F6Publishing: 67] [Article Influence: 12.6] [Reference Citation Analysis]
464 Lambotin M, Barth H, Moog C, Habersetzer F, Baumert TF, Stoll-Keller F, Fafi-Kremer S. Challenges for HCV vaccine development in HIV-HCV coinfection. Expert Rev Vaccines 2012;11:791-804. [PMID: 22913257 DOI: 10.1586/erv.12.52] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
465 Shoukry NH, Grakoui A, Houghton M, Chien DY, Ghrayeb J, Reimann KA, Walker CM. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med. 2003;197:1645-1655. [PMID: 12810686 DOI: 10.1084/jem.20030239] [Cited by in Crossref: 467] [Cited by in F6Publishing: 434] [Article Influence: 24.6] [Reference Citation Analysis]
466 Racanelli V, Behrens SE, Aliberti J, Rehermann B. Dendritic cells transfected with cytopathic self-replicating RNA induce crosspriming of CD8+ T cells and antiviral immunity. Immunity 2004;20:47-58. [PMID: 14738764 DOI: 10.1016/s1074-7613(03)00353-4] [Cited by in Crossref: 40] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
467 Candotti D, Temple J, Sarkodie F, Allain JP. Frequent recovery and broad genotype 2 diversity characterize hepatitis C virus infection in Ghana, West Africa. J Virol. 2003;77:7914-7923. [PMID: 12829831 DOI: 10.1128/jvi.77.14.7914-7923.2003] [Cited by in Crossref: 95] [Cited by in F6Publishing: 37] [Article Influence: 5.0] [Reference Citation Analysis]
468 Osburn WO, Snider AE, Wells BL, Latanich R, Bailey JR, Thomas DL, Cox AL, Ray SC. Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses. Hepatology 2014;59:2140-51. [PMID: 24425349 DOI: 10.1002/hep.27013] [Cited by in Crossref: 154] [Cited by in F6Publishing: 151] [Article Influence: 19.3] [Reference Citation Analysis]
469 De Re V, Sansonno D, Simula MP, Caggiari L, Gasparotto D, Fabris M, Tucci FA, Racanelli V, Talamini R, Campagnolo M. HCV-NS3 and IgG-Fc crossreactive IgM in patients with type II mixed cryoglobulinemia and B-cell clonal proliferations. Leukemia. 2006;20:1145-1154. [PMID: 16617326 DOI: 10.1038/sj.leu.2404201] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 3.2] [Reference Citation Analysis]
470 Callender GG, Rosen HR, Roszkowski JJ, Lyons GE, Li M, Moore T, Brasic N, McKee MD, Nishimura MI. Identification of a hepatitis C virus-reactive T cell receptor that does not require CD8 for target cell recognition. Hepatology 2006;43:973-81. [PMID: 16628627 DOI: 10.1002/hep.21157] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
471 Badr G, Bédard N, Abdel-Hakeem MS, Trautmann L, Willems B, Villeneuve JP, Haddad EK, Sékaly RP, Bruneau J, Shoukry NH. Early interferon therapy for hepatitis C virus infection rescues polyfunctional, long-lived CD8+ memory T cells. J Virol. 2008;82:10017-10031. [PMID: 18667516 DOI: 10.1128/jvi.01083-08] [Cited by in Crossref: 108] [Cited by in F6Publishing: 73] [Article Influence: 7.7] [Reference Citation Analysis]
472 Ayoub HH, Chemaitelly H, Omori R, Abu-Raddad LJ. Hepatitis C virus infection spontaneous clearance: Has it been underestimated? Int J Infect Dis 2018;75:60-6. [PMID: 30031139 DOI: 10.1016/j.ijid.2018.07.013] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
473 Sun W, Li Q, Zhu D, Feng J, Zhuang Z, Sun X, Xiao G, Duan Y. Enhancement of immune response to a hepatitis C virus E2 DNA vaccine by an immunoglobulin Fc fusion tag. J Med Virol 2015;87:2090-7. [PMID: 26010499 DOI: 10.1002/jmv.24277] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
474 Mueller M, Spangenberg HC, Kersting N, Altay T, Blum HE, Klenerman P, Thimme R, Semmo N. Virus-specific CD4+ T cell responses in chronic HCV infection in blood and liver identified by antigen-specific upregulation of CD154. Journal of Hepatology 2010;52:800-11. [DOI: 10.1016/j.jhep.2009.12.038] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
475 Klenerman P, Lucas M, Barnes E, Harcourt G. Immunity to hepatitis C virus: stunned but not defeated. Microbes Infect 2002;4:57-65. [PMID: 11825776 DOI: 10.1016/s1286-4579(01)01510-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
476 Perney P, Portal??s P, Corbeau P, Roques V, Blanc F, Clot J. Specific Alteration of Peripheral Cytotoxic Cell Perforin Expression in Alcoholic Patients: A Possible Role in Alcohol-Related Diseases: . Alcoholism: Clinical & Experimental Research 2003;27:1825-30. [DOI: 10.1097/01.alc.0000093742.22787.30] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
477 Ramadori G, Meier V. Hepatitis C virus infection: 10 years after the discovery of the virus. Eur J Gastroenterol Hepatol 2001;13:465-71. [PMID: 11396522 DOI: 10.1097/00042737-200105000-00001] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.0] [Reference Citation Analysis]
478 Elliot LN, Lloyd AR, Ziegler JB, Ffrench RA. Protective immunity against hepatitis C virus infection. Immunol Cell Biol 2006;84:239-49. [PMID: 16509830 DOI: 10.1111/j.1440-1711.2006.01427.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 1.7] [Reference Citation Analysis]
479 Grebely J, Matthews GV, Dore GJ. Treatment of acute HCV infection. Nat Rev Gastroenterol Hepatol 2011;8:265-74. [DOI: 10.1038/nrgastro.2011.32] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 3.6] [Reference Citation Analysis]
480 Yang D, Liu N, Zuo C, Lei S, Wu X, Zhou F, Liu C, Zhu H. Innate host response in primary human hepatocytes with hepatitis C virus infection. PLoS One. 2011;6:e27552. [PMID: 22087337 DOI: 10.1371/journal.pone.0027552] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
481 Houldsworth A, Metzner M, Rossol S, Shaw S, Kaminski E, Demaine AG, Cramp ME. Polymorphisms in the IL-12B Gene and Outcome of HCV Infection. Journal of Interferon & Cytokine Research 2005;25:271-6. [DOI: 10.1089/jir.2005.25.271] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 2.0] [Reference Citation Analysis]
482 Yu H, Babiuk LA, van Drunen Littel-van den Hurk S. Priming with CpG-enriched plasmid and boosting with protein formulated with CpG oligodeoxynucleotides and Quil A induces strong cellular and humoral immune responses to hepatitis C virus NS3. J Gen Virol. 2004;85:1533-1543. [PMID: 15166437 DOI: 10.1099/vir.0.79821-0] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 1.5] [Reference Citation Analysis]
483 Wedemeyer H, He XS, Nascimbeni M, Davis AR, Greenberg HB, Hoofnagle JH, Liang TJ, Alter H, Rehermann B. Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol. 2002;169:3447-3458. [PMID: 12218168 DOI: 10.4049/jimmunol.169.6.3447] [Cited by in Crossref: 487] [Cited by in F6Publishing: 472] [Article Influence: 24.4] [Reference Citation Analysis]
484 Brochado-Kith Ó, Gómez Sanz A, Real LM, Crespo García J, Ryan Murúa P, Macías J, Cabezas González J, Troya J, Pineda JA, Arias Loste MT, Díez Viñas V, Jiménez-Sousa MÁ, Medrano de Dios LM, Cuesta De la Plaza I, Monzón Fernández S, Resino García S, Fernández-Rodríguez A. MicroRNA Profile of HCV Spontaneous Clarified Individuals, Denotes Previous HCV Infection. J Clin Med 2019;8:E849. [PMID: 31207946 DOI: 10.3390/jcm8060849] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
485 Diepolder HM. New insights into the immunopathogenesis of chronic hepatitis C. Antiviral Res 2009;82:103-9. [PMID: 19428600 DOI: 10.1016/j.antiviral.2009.02.203] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
486 Molina PE, Hoek JB, Nelson S, Guidot DM, Lang CH, Wands JR, Crawford JM. Mechanisms of alcohol-induced tissue injury. Alcohol Clin Exp Res 2003;27:563-75. [PMID: 12658123 DOI: 10.1097/01.ALC.0000057946.57330.F7] [Cited by in Crossref: 44] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
487 Takaki A, Tatsukawa M, Iwasaki Y, Koike K, Noguchi Y, Shiraha H, Sakaguchi K, Nakayama E, Yamamoto K. Hepatitis C virus NS4 protein impairs the Th1 polarization of immature dendritic cells. J Viral Hepat. 2010;17:555-562. [PMID: 19804500 DOI: 10.1111/j.1365-2893.2009.01213.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
488 Santolamazza M, Marinelli RM, Bacosi M, D'Innocenzo S, Miglioresi L, Patrizi F, Delle Monache M, Ricci GL. What kind of hepatitis? J Int Med Res 2001;29:441-4. [PMID: 11725833 DOI: 10.1177/147323000102900510] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
489 Grebely J, Prins M, Hellard M, Cox AL, Osburn WO, Lauer G, Page K, Lloyd AR, Dore GJ. Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis. 2012;12:408-414. [PMID: 22541630 DOI: 10.1016/s1473-3099(12)70010-5] [Cited by in Crossref: 144] [Cited by in F6Publishing: 73] [Article Influence: 14.4] [Reference Citation Analysis]
490 Santantonio T, Sinisi E, Guastadisegni A, Casalino C, Mazzola M, Gentile A, Leandro G, Pastore G. Natural course of acute hepatitis C: a long-term prospective study. Dig Liver Dis. 2003;35:104-113. [PMID: 12747629 DOI: 10.1016/s1590-8658(03)00007-0] [Cited by in Crossref: 70] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
491 Desai SN, Dodge JL, Landay AL, Glesby MJ, Latham PS, Villacres MC, French AL, Gange SJ, Greenblatt RM, Peters MG. Hepatic fibrosis and immune phenotype vary by HCV viremia in HCV/HIV co-infected subjects: A Women's interagency HIV study. Medicine (Baltimore) 2016;95:e4483. [PMID: 27537569 DOI: 10.1097/MD.0000000000004483] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
492 Pham TN, King D, Macparland SA, McGrath JS, Reddy SB, Bursey FR, Michalak TI. Hepatitis C virus replicates in the same immune cell subsets in chronic hepatitis C and occult infection. Gastroenterology. 2008;134:812-822. [PMID: 18243182 DOI: 10.1053/j.gastro.2007.12.011] [Cited by in Crossref: 99] [Cited by in F6Publishing: 96] [Article Influence: 6.6] [Reference Citation Analysis]
493 Frey SE, Houghton M, Coates S, Abrignani S, Chien D, Rosa D, Pileri P, Ray R, Di Bisceglie AM, Rinella P, Hill H, Wolff MC, Schultze V, Han JH, Scharschmidt B, Belshe RB. Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine. 2010;28:6367-6373. [PMID: 20619382 DOI: 10.1016/j.vaccine.2010.06.084] [Cited by in Crossref: 152] [Cited by in F6Publishing: 142] [Article Influence: 12.7] [Reference Citation Analysis]
494 Takao Y, Yamada A, Yutani S, Ono T, Nagao Y, Ando E, Ide T, Itoh K, Sata M. Serum levels of IgG to the peptide of HCV1b core at positions 35-44 correlated with persistent infection, while levels of IgG to the peptide of NS5A at positions 2132-2140 correlated with better prognosis in HCV-infected patients. Med Microbiol Immunol 2007;196:157-64. [PMID: 17574493 DOI: 10.1007/s00430-007-0038-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
495 Fang Z, Zhu K, Guo N, Zhang N, Guan M, Yang C, Pan Q, Wei R, Yang C, Deng C, Liu X, Zhao P, Leng Q. HCV J6/JFH1 tilts the capability of myeloid-derived dendritic cells to favor the induction of immunosuppression and Th17-related inflammatory cytokines. Pharm Res 2015;32:741-8. [PMID: 23619596 DOI: 10.1007/s11095-013-1050-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
496 Gorodin S, Unal S, Wang Y, Mikhaylov MI, Bigbulatova L, Jehuda-Cohen T. New tools in HCV diagnosis, in light of the enhanced awareness and the new drugs for treatment: SMARTube and stimmunology. ScientificWorldJournal 2013;2013:389780. [PMID: 23476130 DOI: 10.1155/2013/389780] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
497 Anthony DD, Valdez H, Post AB, Carlson NL, Heeger PS, Lehmann PV. Comprehensive Determinant Mapping of the Hepatitis C-Specific CD8 Cell Repertoire Reveals Unpredicted Immune Hierarchy. Clinical Immunology 2002;103:264-76. [DOI: 10.1006/clim.2001.5193] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
498 Daar ES, Lynn H, Donfield S, Gomperts E, Hilgartner MW, Hoots WK, Chernoff D, Arkin S, Wong W, Winkler CA. Relation Between HIV-1 and Hepatitis C Viral Load in Patients With Hemophilia: . Journal of Acquired Immune Deficiency Syndromes 2001;26:466-72. [DOI: 10.1097/00042560-200104150-00011] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
499 Nemes B, Sárváry E, Gerlei Z, Fazakas J, Doros A, Németh A, Görög D, Fehérvári I, Máthé Z, Gálffy Z, Pár A, Schuller J, Telegdy L, Fehér J, Lotz G, Schaff Z, Nagy P, Járay J, Lengyel G. The recurrence of hepatitis C virus after liver transplantation. Orvosi Hetilap 2007;148:1971-9. [DOI: 10.1556/oh.2007.28176] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
500 Abdelwahab SF, Hashem M, Galal I, Sobhy M, Abdel-ghaffar TS, Galal G, Mikhail N, El-kamary SS, Waked I, Strickland GT. Incidence of hepatitis C virus infection among Egyptian healthcare workers at high risk of infection. Journal of Clinical Virology 2013;57:24-8. [DOI: 10.1016/j.jcv.2013.01.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
501 Wang JH, Layden TJ, Eckels DD. Modulation of the peripheral T-Cell response by CD4 mutants of hepatitis C virus: transition from a Th1 to a Th2 response. Human Immunology 2003;64:662-73. [DOI: 10.1016/s0198-8859(03)00070-3] [Cited by in Crossref: 41] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
502 Shin EC, Protzer U, Untergasser A, Feinstone SM, Rice CM, Hasselschwert D, Rehermann B. Liver-directed gamma interferon gene delivery in chronic hepatitis C. J Virol 2005;79:13412-20. [PMID: 16227262 DOI: 10.1128/JVI.79.21.13412-13420.2005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
503 Godkin A, Openshaw P, Thomas HC. Immune tolerance to hepatitis C virus acquired during engraftment of bone marrow transplant. J Viral Hepat 2005;12:604-8. [PMID: 16255761 DOI: 10.1111/j.1365-2893.2005.00627.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
504 Maylin S, Martinot-Peignoux M, Ripault MP, Moucari R, Cardoso AC, Boyer N, Giuily N, Castelnau C, Pouteau M, Asselah T, Nicolas-Chanoine MH, Marcellin P. Sustained virological response is associated with clearance of hepatitis C virus RNA and a decrease in hepatitis C virus antibody. Liver Int 2009;29:511-7. [PMID: 19076273 DOI: 10.1111/j.1478-3231.2008.01918.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
505 Kaźmierczak J, Pawełczyk A, Cortes KC, Radkowski M. Seronegative hepatitis C virus infection. Arch Immunol Ther Exp (Warsz) 2014;62:145-51. [PMID: 24202543 DOI: 10.1007/s00005-013-0257-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
506 Park SH, Bang CS, Kim DJ. Biomarkers in HCV Infection. Adv Clin Chem 2015;70:131-96. [PMID: 26231487 DOI: 10.1016/bs.acc.2015.03.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
507 Neumann-Haefelin C, Spangenberg HC, Blum HE, Thimme R. Host and viral factors contributing to CD8+ T cell failure in hepatitis C virus infection. World J Gastroenterol 2007; 13(36): 4839-4847 [PMID: 17828815 DOI: 10.3748/wjg.v13.i36.4839] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 33] [Article Influence: 2.4] [Reference Citation Analysis]
508 Abdelwahab SF. Cellular immune response to hepatitis-C-virus in subjects without viremia or seroconversion: is it important? Infect Agent Cancer 2016;11:23. [PMID: 27186234 DOI: 10.1186/s13027-016-0070-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
509 Thimme R, Binder M, Bartenschlager R. Failure of innate and adaptive immune responses in controlling hepatitis C virus infection. FEMS Microbiol Rev 2012;36:663-83. [DOI: 10.1111/j.1574-6976.2011.00319.x] [Cited by in Crossref: 94] [Cited by in F6Publishing: 90] [Article Influence: 9.4] [Reference Citation Analysis]
510 Yoshio S, Sugiyama M, Shoji H, Mano Y, Mita E, Okamoto T, Matsuura Y, Okuno A, Takikawa O, Mizokami M. Indoleamine-2,3-dioxygenase as an effector and an indicator of protective immune responses in patients with acute hepatitis B. Hepatology. 2016;63:83-94. [PMID: 26458241 DOI: 10.1002/hep.28282] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
511 Radkowski M, Gallegos-Orozco JF, Jablonska J, Colby TV, Walewska-Zielecka B, Kubicka J, Wilkinson J, Adair D, Rakela J, Laskus T. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology. 2005;41:106-114. [PMID: 15619235 DOI: 10.1002/hep.20518] [Cited by in Crossref: 225] [Cited by in F6Publishing: 216] [Article Influence: 13.2] [Reference Citation Analysis]
512 Farmand S, Wirth S, Löffler H, Woltering T, Kenzel S, Lainka E, Henneke P. Spontaneous clearance of hepatitis C virus in vertically infected children. Eur J Pediatr. 2012;171:253-258. [PMID: 21735055 DOI: 10.1007/s00431-011-1517-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
513 Li T, Chen Z, Zeng J, Zhang J, Wang W, Zhang L, Zheng X, Shuai L, Klenerman P, Allain JP, Li C. Impact of host responses on control of hepatitis C virus infection in Chinese blood donors. Biochem Biophys Res Commun 2011;415:503-8. [PMID: 22062549 DOI: 10.1016/j.bbrc.2011.10.102] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
514 Hashem M, El-Karaksy H, Shata MT, Sobhy M, Helmy H, El-Naghi S, Galal G, Ali ZZ, Esmat G, Abdelwahab SF. Strong hepatitis C virus (HCV)-specific cell-mediated immune responses in the absence of viremia or antibodies among uninfected siblings of HCV chronically infected children. J Infect Dis. 2011;203:854-861. [PMID: 21257736 DOI: 10.1093/infdis/jiq123] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
515 Prezzi C, Casciaro M, Francavilla V, Schiaffella E, Finocchi L, Chircu L, Bruno G, Sette A, Abrignani S, Barnaba V. Virus-specific CD8+ T cells with type 1 or type 2 cytokine profile are related to different disease activity in chronic hepatitis C virus infection. Eur J Immunol 2001;31:894-906. [DOI: 10.1002/1521-4141(200103)31:3<894::aid-immu894>3.0.co;2-i] [Cited by in Crossref: 68] [Cited by in F6Publishing: 26] [Article Influence: 3.2] [Reference Citation Analysis]
516 Reiche S, Nestler C, Sieg M, Schulz K, Cordes C, Krznaric I, Jassoy C. Hepatitis C virus (HCV)-specific memory B-cell responses in transiently and chronically infected HIV positive individuals. J Clin Virol 2014;59:218-22. [PMID: 24566009 DOI: 10.1016/j.jcv.2014.01.023] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
517 Feld JJ, Liang TJ. HCV persistence: cure is still a four letter word. Hepatology. 2005;41:23-25. [PMID: 15690477 DOI: 10.1002/hep.20561] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.1] [Reference Citation Analysis]
518 Rehermann B. Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Nat Med 2013;19:859-68. [PMID: 23836236 DOI: 10.1038/nm.3251] [Cited by in Crossref: 291] [Cited by in F6Publishing: 288] [Article Influence: 32.3] [Reference Citation Analysis]
519 Darling JM, Wright TL. Immune responses in hepatitis C: is virus or host the problem?: . Current Opinion in Infectious Diseases 2004;17:193-8. [DOI: 10.1097/00001432-200406000-00004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
520 Gelderblom HC, Nijhuis LE, de Jong EC, te Velde AA, Pajkrt D, Reesink HW, Beld MG, van Deventer SJ, Jansen PL. Monocyte-derived dendritic cells from chronic HCV patients are not infected but show an immature phenotype and aberrant cytokine profile. Liver Int. 2007;27:944-953. [PMID: 17696933 DOI: 10.1111/j.1478-3231.2007.01507.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
521 Meyer-Olson D, Shoukry NH, Brady KW, Kim H, Olson DP, Hartman K, Shintani AK, Walker CM, Kalams SA. Limited T cell receptor diversity of HCV-specific T cell responses is associated with CTL escape. J Exp Med. 2004;200:307-319. [PMID: 15289502 DOI: 10.1084/jem.20040638] [Cited by in Crossref: 132] [Cited by in F6Publishing: 125] [Article Influence: 7.3] [Reference Citation Analysis]
522 Pham TN, MacParland SA, Mulrooney PM, Cooksley H, Naoumov NV, Michalak TI. Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. J Virol. 2004;78:5867-5874. [PMID: 15140984 DOI: 10.1128/jvi.78.11.5867-5874.2004] [Cited by in Crossref: 235] [Cited by in F6Publishing: 78] [Article Influence: 13.1] [Reference Citation Analysis]
523 Huang L, Koziel MJ. Immunology of hepatitis C virus infection: . Current Opinion in Gastroenterology 2000;16:558-64. [DOI: 10.1097/00001574-200011000-00017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
524 Sharma SA, Feld JJ. Acute Hepatitis C: Management in the Rapidly Evolving World of HCV. Curr Gastroenterol Rep 2014;16. [DOI: 10.1007/s11894-014-0371-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
525 Mondelli MU. Neonatal blood microtransfusions and hepatitis C virus infection. Lancet 2001;357:1363. [PMID: 11347580 DOI: 10.1016/S0140-6736(00)04485-8] [Reference Citation Analysis]
526 Zhang M, Rosenberg PS, Brown DL, Preiss L, Konkle BA, Eyster ME, Goedert JJ. Correlates of spontaneous clearance of hepatitis C virus among people with hemophilia. Blood. 2006;107:892-897. [PMID: 16204310 DOI: 10.1182/blood-2005-07-2781] [Cited by in Crossref: 61] [Cited by in F6Publishing: 61] [Article Influence: 3.6] [Reference Citation Analysis]
527 Sugimoto K, Shiraki K. Different aspects of CD4 T cells that lead to viral clearance or persistence of HCV infection. Hepatol Int 2012;6:350-5. [PMID: 26201340 DOI: 10.1007/s12072-011-9321-8] [Reference Citation Analysis]
528 Shata MT, Barrett A, Shire NJ, Abdelwahab SF, Sobhy M, Daef E, El-Kamary SS, Hashem M, Engle RE, Purcell RH. Characterization of hepatitis E-specific cell-mediated immune response using IFN-γ ELISPOT assay. J Immunol Methods. 2007;328:152-161. [PMID: 17905301 DOI: 10.1016/j.jim.2007.08.014] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 2.3] [Reference Citation Analysis]
529 Kaplan DE, Ikeda F, Li Y, Nakamoto N, Ganesan S, Valiga ME, Nunes FA, Rajender Reddy K, Chang KM. Peripheral virus-specific T-cell interleukin-10 responses develop early in acute hepatitis C infection and become dominant in chronic hepatitis. J Hepatol. 2008;48:903-913. [PMID: 18384906 DOI: 10.1016/j.jhep.2008.01.030] [Cited by in Crossref: 59] [Cited by in F6Publishing: 55] [Article Influence: 4.2] [Reference Citation Analysis]
530 Carlos MP, Yamamura Y, Vu Q, Conzen K, Anderson DE, Torres JV. Humoral immunity to immunodominant epitopes of Hepatitis C virus in individuals infected with genotypes 1a or 1b. Clin Immunol. 2004;111:22-27. [PMID: 15093548 DOI: 10.1016/j.clim.2003.11.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
531 Dreux M, Cosset F. The scavenger receptor BI and its ligand, HDL: partners in crime against HCV neutralizing antibodies. J Viral Hepat 2007;14:68-76. [DOI: 10.1111/j.1365-2893.2007.00919.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]